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The diagnosis of tuberculosis (TB) disease remains a challenge. This is mainly due to 
limitations with the current TB diagnostic tests including unavailability of rapid point-
of-care tests. New TB diagnostic tests are therefore urgently needed. The 
QuantiFERON-TB® Gold (QFT) Plus test is a recently introduced test for the diagnosis 
of M. tb infection, and disease in some patient groups. As this is a relatively new test 
which is currently in use worldwide, it is important that its performance be evaluated, 
especially in high TB burden settings. Furthermore, it is not known whether 
measurement of host markers other than Interferon-gamma in culture supernatants of 
individuals with active TB or other respiratory diseases (ORD), has potential in the 
diagnosis of TB disease.  
 
OBJECTIVES 
1) To evaluate the usefulness of the QFT Plus test in the diagnosis of TB disease, 
and assess the utility of the test, when used in combination with symptoms, as 
a tool for diagnosis of TB disease in people suspected of having active TB in a 
high burden setting.  
2) To evaluate alternative host biomarkers detected in QFT Plus supernatants, 
other than IFN-γ as biosignatures for the diagnosis of active TB 
 
METHODS 
We recruited 120 participants presenting at a primary health care clinics in Cape Town, 
South Africa with symptoms requiring investigation for TB disease. These participants 
formed part of a larger ongoing biomarker project known as the ‘ScreenTB’ study. 
Participants were later classified as TB or ORD based on the results of clinical and 
laboratory tests. After performing the standard QFT Plus test in study participants, the 
concentrations of 37 host biomarkers were evaluated in culture supernatants using a 
multiplex immunoassay.  






Out of 120 individuals included in the study, 35 (29.2%) were diagnosed with active 
TB and were culture positive. The QFT Plus test diagnosed TB disease in all study 
participants with sensitivity and specificity >70%. A combination of symptoms including 
cough, fever and weight loss diagnosed TB disease with sensitivity and specificity 
>70% with an area under the receiver operator characteristics curve of 0.81. Multiple 
host biomarkers detected in the unstimulated and antigen-stimulated QFT Plus tubes 
showed potential as diagnostic markers for TB. Individual markers which diagnosed 
TB disease with sensitivities and specificities >60% included ITAC-1, IL-3, I-309, MIG, 
and EGF, P-selectin. Combinations between host biomarkers showed potential in the 
diagnosis of TB disease with a six-marker biosignature derived from unstimulated 
supernatants (APO-CII, ITAC-1, MIG, MCP-2, I-309, and NCAM-1) diagnosing TB 
disease with a sensitivity and specificity >78%, a four-marker TB1 and TB2 antigen-
specific biosignature (TNFα, LIGHT, MIG and P-selectin ) which diagnosed TB disease 
with sensitivity and specificity >73%, after leave-one-out cross validation. 
 
CONCLUSION 
The sensitivity of the QFT Plus test for active TB was inferior to the published >80% 
mentioned in the package insert by the manufacturer. Host biomarkers detected in 
QFT Plus supernatants showed potential in the diagnosis of active TB disease. Further 
validation studies are needed before such markers may be considered as candidate 














Die diagnose van tuberkulose (TB siekte) bly 'n uitdaging. Dit is hoofsaaklik te wyte 
aan beperkinge met die huidige TB diagnostiese toetse, insluitend die beskikbaarheid 
van vinnige punt van soegtoetse. Nuwe TB diagnostiese toetse is dus dringend nodig. 
Die QuantiFERON-TB® Goud (QFT) Plus toets is 'n onlangs ontwikkelde toets vir die 
diagnose van M. tb infeksie en tuberkulose in sommige pasiëntgroepe. Aangesien dit 
'n relatief nuwe toets is wat tans wêreldwyd gebruik word, is dit belangrik dat die 
prestasie vd toets geëvalueer word, veral in hoë TB-lasinsweld dtrelie tellings. Verder 
is dit nie bekend of meting van gasheermerkers behalwe Interferon-gamma in kweek 
supernatante van individue met aktiewe TB of ander respiratoriese siektes (ORD), 
potensiaal het in die diagnose van TB-siekte. 
 
DOELWITTE 
1) Om die nut van die QFT Plus-toets in die diagnose van TB-siekte te evalueer, 
wanneer dit in kombinasie met simptome gebruik word, as 'n instrument vir die 
diagnose van TB-siekte by mense wat vermoed word dat hulle aktiewe TB heit in 'n 
hoë lastrehe. 
 
2) Om alternatiewe gasheerbiomerkers wat in QFT Plus supernatante aangetref word, 
te evalueer, anders as IFN-γ as biomeker vir die diagnose van aktiewe TB 
 
METODES 
Ons het 120 deelnemers gewerf by 'n primêre gesondheidsorgkliniek in Kaapstad, 
Suid-Afrika, met simptome wat ondersoek na TB-siekte vereis. Hierdie deelnemers 
het deel gevorm van 'n groter voortgesette biomerkerprojek wat bekend staan as die 
'ScreenTB'-studie. Deelnemers is geklassifiseer as TB of ORD gebaseer op die 
resultate van kliniese en laboratoriumtoetse. Nadat die standaard QFT Plus-toets in 
studie-deelnemers uitgevoer is, is die konsentrasies van 37 gasheerbiomerkers 
geëvalueer in kweek supernatante met behulp van 'n veelvuldige imuuufoetse. 
 
 





Uit 120 individue wat in die studie ingesluit is, is 35 (29,2%) met aktiewe TB 
gediagnoseer en was kultuur positief. Die QFT Plus-toets het TB-siektes in alle studie-
deelnemers met 'n sensitiwiteit en spesifisiteit van> 70% gediagnoseer. 'n Kombinasie 
van simptome soos hoes, koors en gewigsverlies diagnoseer TB siekte met 
sensitiwiteit en spesifisiteit> 70% met 'n gebied onder die ontvanger operateur 
eienskappe kurwe van 0.81. Veelvuldige gasheerbiomerkers wat in die 
ongestimuleerde en antigeen-gestimuleerde QFT Plus-buise opgespoor is, het 
potensiaal as diagnostiese merkers vir TB vertoon. Individuele merkers wat TB-siekte 
gediagnoseer het met sensitiwiteit en spesifieke eienskappe> 60% sluit in ITAC-1, IL-
3, I-309, MIG en EGF, P-selektien. Kombinasies tussen gasheerbiomarkers het 
potensiaal getoon in die diagnose van TB-siekte. Ses biomakers van ongestimuleerde 
supernatante (APO-CII, ITAC-1, MIG, MCP-2, I-309, en NCAM-1) het 'n sensitiwiteit 
en spesifisiteit getoon van >78%. Die vier-biomeker TB1 en TB2 antigenspesifieke 
kombinasie (TNFa, LIG, MIG en P-selektien) het TB slette gecliagnoseer met 'n 
sensitiwiteit en spesifisileit >73% na verlof-een-uit kruis validasie. 
 
AFSLUITING 
Die sensitiwiteit van die QFT Plus-toets vir aktiewe TB was nie soos die 
gepubliseerde> 80% wat in die pakketstuk deur die vervaardiger genoem word nie. 
Gasheer biomerkers wat in QFT Plus supernatante aangetoon is, het potensiaal 
getoon in die diagnose van aktiewe TB-siekte. Verdere valideringstudies is nodig 
voordat sulke merkers as kandidaat-biomerkers beskou kan word vir 'n 
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Mycobacterium tuberculosis (M. tb) is an aerobic pathogenic bacterium that causes 
tuberculosis (TB) (1). M. tb, together with nine other mycobacterium species (M. 
africanam, M. bovis, M. caprae, M. microti, M.pinnipedii, M.africanum, M. mungi, M. 
orygis and M. tuberculosis sensi stricto) belongs to the family of Mycobactericeae (2). 
M. tb can appear as either Gram positive or Gram negative due to the presence of 
mycolic acids on its cell wall. Its lipids are the key virulence factors which also helps it 
to survive in a dry state for weeks. It can be identified with a microscope by using acid 
fast stains such as Zeihl-Neelsen, or fluorescent stains such as auramine (3). 
M. tb is a pathogen of the mammalian respiratory system and its biology requires high 
levels of oxygen because it is highly aerobic (4).  Lungs are the main body organs 
which are affected by TB (pulmonary TB), however other body parts can also be 
affected (extra-pulmonary TB) (1). M. tb is known to divide every 15 to 20 hours which 
is very slow when compared to other bacteria (5). TB is spread through air droplets 
containing bacilli which originate from a person with pulmonary active TB by either 
speaking, coughing, singing or sneezing. These droplets range from 0.5 to 5.0 µm in 
diameter and a single sneeze is capable of releasing up to 40 000 droplets. HIV 
amongst other TB comorbidities (diabetes and nutrition, tobacco smoking and harmful 
use of alcohol) is the main risk factor for developing active TB disease in people who 
are latently infected with M. tb. However, TB is also a main leading course of death in 
people living with HIV infection. People living with HIV infection have weak immune 
systems which are therefore favourable conditions for opportunistic bacteria such as 
M. tb to progress. Since TB disease depends on cell mediated immune response with 
CD4+ T cells being the main lymphocytes involved, people who have HIV already have 
low CD4 T cell counts. This therefore means that the immune system is unable to fight 
against two diseases at the same time, frequently resulting in death. 
 




1.2 Tuberculosis epidemiology 
 
The World Health Organisation (WHO) reported that TB is the ninth leading cause of 
death globally, and ranks above HIV/AIDS (6). The TB mortality rate has fallen globally 
at around 3% annually and the global incidence rate at around 2% annually. Although 
the mortality and incidence has decreased, WHO estimates reveal that the decline is 
not sufficient, and that the TB incidence rate should decrease from 4 to 5% annually 
by 2020, for us to meet the goals of the End TB strategy. It was estimated that 10million 
people fell ill with TB, and a total of 1.3 million died as a result of the disease in 2017 
(Figure 1.1). Among the overall estimated 1.7 billion, 90% were adults, 64% male, and 
9% (400 000) were living with HIV (figure 1.2). WHO also reported that South-East 
Asia and Africa regions had the most TB incidences with 45% and 25% respectively 
(6). 
 
Figure 1.1: Estimated TB incidence in 2017 in countries with at least 100 000 
incident cases. Source:  WHO Global TB Report, 2018 (6). 
 





Figure 1.2: Estimated HIV prevalence in new and relapse TB cases in 2017. Source: 
WHO Global TB Report, 2018 (6). 
 
1.3 Basic immunological principles relevant to the immune response against 
infectious diseases 
 
Immunology refers to the body’s immune defence against microorganisms capable of 
causing diseases as well as immune disorders. When the human body is exposed to 
different microorganisms, the immune system is activated in order to fight against 
these microorganisms, with the purpose of eliminating them. The immune system 
consists of a network of immune cells, tissues and organs which work together and 
mediate the immune response to protect the body (7). However, white blood cells (also 
called leukocytes) are the main players of the body’s immune response against 
disease causing organisms. These cells are found or stored in different locations such 
as the bone marrow, thymus and spleen. In order for the immune system to work in a 
coordinated manner, these leukocytes circulate within the nodes and organs 
throughout the body via blood and lymphatic vessels (8). Phagocytes and lymphocytes 
are the two types of leukocytes which are known to digest invading organisms and 
enables the body to remember and recognize the past invaders and also helps the 




immune system to eliminate them. The immune protection against disease is mainly 
mediated by natural (innate) and adaptive (9). 
 
1.3.1 Innate immunity 
 
The innate immunity plays an important role during infection as a non-specific defence 
mechanism, which happens immediately or as a first line of defence against invaders 
in the body (10). This type of immunity makes use of various mechanisms including 
external surfaces of the body such as physical barriers (the skin and mucus 
membranes), chemical barriers found in the blood, as well as the other immune cells 
which prevent invaders or organisms from entering the body. Natural immunity also 
recruits immune cells (neutrophils, mast cells, dendritic cells macrophages, 
basophiles, eosinophils and natural killer cells) to the site of infection wherein they 
produce chemical factors and chemical mediators such as cytokines (11). It is 
responsible for activating the complement system which identifies and removes 
bacteria or any foreign substances. The innate immune system also plays the 
important role of activating the adaptive immune system through presentation of 
antigens from innate cells to the adaptive cells (11). 
 
1.3.2 Adaptive immunity 
 
The adaptive immune response makes use of more specialised groups of cells in order 
to fight against foreign substances or bacteria and to also prevent or eliminate them 
from re-occurring through immunological memory (11). This type of immune response 
consists of cell mediated immune responses and antibody responses which are 
mediated by B cells and T cells. In antibody immune response, B cells are transformed 
to plasma cells which secrete antibodies (Abs) which circulate through the blood and 
lymph where they bind to specific foreign antigens (Ags) to inactivate microbial toxins 
and prevent them from attaching to the host cell receptors (12). During cell mediated 
immune response, macrophages, lymphocytes, antigen specific cytotoxic T 
lymphocytes are activated and release cytokines to fight against specific antigens. For 




this thesis, we will focus on cell mediated immune responses which will involve the 
importance of T lymphocytes during M. tb infection (2). 
 
1.4 Immunology of tuberculosis 
 
Following the inhalation of M. tb bacilli into the lungs. The bacilli can undergo important 
fates were the bacilli can eliminate all bacilli such that the host never develops TB in 
the future, or the organism can grow and divide just after infection resulting in a clinical 
disease referred to as clinical infection, the bacilli can remain dormant and do not 
cause TB disease or the dormant/latent bacilli eventually begins to grow which will 
therefore result in clinical disease referred to as tuberculosis reactivation (13). 
Although M. tb bacilli remain dormant in most of the hosts, studies have shown that in 
all individuals with latent tuberculosis infection (LTBI) (discussed in detail below), 
about 3-15% develop active TB disease in their lifetime (14).  Furthermore, other 
studies showed that reactivation of active TB can be as low as 1% over a period of 7 
years (15). Additionally, individuals with compromised immune systems such as 
children and HIV infected individuals have around 7% chance of developing active TB 
disease every year post LTBI (16). 
It is believed that, once M. tb reaches the host’s lower respiratory tract, the initial host 
defence is mediated by alveolar macrophages which inhibit M. tb bacilli growth through 
phagocytosis. Briefly, during the process of phagocytosis, macrophages binds to M. 
tb bacilli and internalize them followed by killing of the bacteria. The complement 
system plays an important role during the process of phagocytosis. Experimental 
evidence shows that during phagocytosis process, the creation of a phagosome is 
followed by binding of M. tb to the phagocyte via complement receptors (CR1, CR2, 
and CR4), mannose binding receptors as well as other receptors at the cell surface 
(17). Prostaglandin E2 (PGE2), IL-4 and IFN-γ are some of the mediators which are 
activated by macrophages expressing mannose and complement receptors. PGE and 
cytokine receptors are known to be involved in upregulation of mannose and 
complement receptors and interferon gamma (IFN-γ) has been shown to have an 
effect on decreasing receptor function and receptor expression which therefore leads 
to inability of M. tb to adhere to the macrophage (18, 19). However mycobacterial 




inhibition also involves other immune cells which help macrophages to control M. tb 
growth (20). Activated macrophages recruit and stimulate T lymphocytes during cell 
mediated immunity which then inhibits microbial growth (21). Although known to ingest 
macrophages which have engulfed M. tb bacilli, they can also produce small proteins 
such as T-cell restricted intracellular antigen-1 (TIA-1) which is a molecule found in 
the cytoplasm and has been demonstrated to induce apoptosis (22). Furthermore, 
macrophages also interact with other effector cells with cytokines and chemokines in 
the background. The role of these molecules is to attract and activate other 
inflammatory effector cells. Interleukin 8 (IL-8) is a vital chemokine from the CXC 
family, which is involved in mycobacterial host pathogen interaction. Its main role is to 
recruit neutrophils, T lymphocytes, and basophils in response to M. tb. IFN-γ and 
transforming growth factor-beta (TGF-β) are the cytokines which many researchers 
have been giving attention to because of their ability to activate and also deactivate 
the ability of macrophage to inhibit M. tb growth respectively. Using variety of animal 
and in vitro experiments, IFN-γ has been demonstrated to play an essential role in 
host defence against M. tb. Several studies investigated the role of IFN-γ in the control 
of M. tb including a study conducted by Holland and colleagues where they found the 
beneficial effect of IFN-γ, when they treated a group of patients suffering from a 
systemic infection caused by non-tuberculous mycobacteria (NTM) and M. avium 
using systemically administered IFN-γ (23). Furthermore, another study by Jaffe and 
colleagues showed that macrophages can be activated by aerosol IFN-γ which was 
given to normal human subjects (24). Other cytokines such as interleukin (IL)-1α/β, IL-
6, have been shown to be involved in host defence against M. tb as well as TNF-α 
which has been shown to play a vital role in TB disease by controlling M. tb infection 
and is also known to play a role in maintaining granulomas (25). Inducible protein 10 
(IP-10) and monocyte chemotactic factor (MCF) also fall under the CXC family of 
chemokines. Macrophage chemotactic protein (MCP-1) chemokine and a regulated 
on activation chemokine known as a normal T cell expressed and secreted (RANTES), 
have been shown to oppose the expression of IL-8 during TB treatment phase 
meaning that when MCP-1 and RANTES decreases IL-8 increases (26). 
 
 




1.5 Role of T lymphocytes during host defence against mycobacteria 
 
The adaptive immune response to M. tb is detectable from three to eight weeks after 
infection wherein, CD4+ T cells are known to play an important role as they are 
primarily involved in immune response against M. tb infection. However, CD8+ T cells 
have also been shown to play an important role in response to M. tb infection. 
Professional antigen presenting cells (APC) are cells whose functions are to process 
antigen proteins after which break them down into peptides and then present them in 
association with major histocompatibility complex (MHC) on their cell surface where 
the peptides can be recognised by T cells. While CD8+ T cells recognise M. tb 
antigens which have been presented by antigen presenting cells (APCs) on their cell 
surfaces from the cytosol through class I MHC molecules, through expression of α and 
β T cell receptors (TCRs), CD4+ T cells recognise antigens presented through MHC 
class II (processed in the phagosome) on the surface of APCs (27). CD4+ cells are 
known to be involved in host immune response amplification through recruiting more 
immune cells to the infection site as well as activation of effector cells. At the same 
time, CD8+ cells are known to have a cytotoxic effect to the targeted cell. The Th1 and 
Th2 cells are phenotypic classes of CD4+ T helper cells which are driven from Th0 
cells. The differentiation of these cells is known to be controlled by different cytokines 
including IL-12 (28, 29, and 30). While Th2 cells are known to produce IL-5, IL-4 and 
IL-10 cytokines and recruiting eosinophils to the site of infection, Th1 cells secrete 
IFN-ү and IL-2, which activate inflammatory and phagocytic cells which are more likely 
to inhibit M. tb growth. However, both Th1 and Th2 may also secrete common 
cytokines such are granulocyte –macrophage colony stimulating factor (GM-CSF) and 
IL-3. 
In the process of antigen driven differentiation, studies have demonstrated that both 
CD8+ and CD4+ T cells secrete more than one cytokine. These types of T cells are 
referred to as polyfunctional T cells. In order for these polyfunctional T cells to be 
characteristic and desirable, studies suggest that they must be tri-functionally 
secreting IL-2, IFN-ү and tumor necrosis factor (TNF) which therefore indicates their 
ability to proliferate and being effective (31). Several studies suggests that in LTBI 
individuals, trifunctional IL-2+ TNF+ IFN-ү+ M. tb specific CD2+ T cells are exhibited 
in higher frequencies whereas greater frequencies of M. tb CD4+ T cells are 




associated with mono or bi functional TNF+ or TNF+IFN-ү in active TB disease (32-
45). 
 
1.6 Spectrum of tuberculosis 
 
During M. tb infection, both latent and replicating bacilli are simultaneously present 
(46). Recent studies suggest that depending on the clinical status (57), adequate 
containment and progression of bacilli to replicate actively resulting in TB disease may 
be understood by dynamic pathology spectrum of sterile tissue, solid caseous and 
necrotic hypoxic lesions which contains unstable numbers of replicating bacilli can be 
detected during active TB (47). With the use of computer tomography and positron 
emission tomography imaging, the imaging results indicates that although these 
heterogeneous lesions coexist simultaneously, they represent various bacilli 
subpopulations in various microenvironments (47). However, studies have shown that 
the same diversity of TB lesions can also be found in LTBI cases which therefore 
suggests that LTBI can be described as a broad spectrum condition overlapping with 
conditions seen in active TB (47, 48). Animal studies have also confirmed that LTBI 
spectrum conditions vary wherein some subjects show a slowly progressing form of 
disease whereas others only show residual infection warning. In the same animal 
model, M. tb replication rate was found to be the same between LTBI and active TB 
which therefore suggests that instead of being in a non-replicating state, it actually 
replicates actively (49,50). 
After primary infection followed by control of M. tb replication through adaptive 
immunity, M. tb may reside in various tissues in a dormant state wherein it intensifies 
its resistance through antimicrobial activities of host immune response (51). When the 
conditions are favourable, the dormant bacteria revives and then initiate active 
replication. However, the replicating bacilli are more likely to be killed in 
immunocompetent hosts which leaves the dormant bacilli predominating. This state is 
referred to as primary disease (52). When the host immune system is unable to control 
the bacilli which is metabolically active, the bacilli becomes activated and replicates 
which leads to secondary active TB disease. Although studies suggest that the 
capacity of the host immune response to clear the infection is dependent on bacterial 




load, the immunological actions for this clearance is still confusing and the research is 
still ongoing. Transient infection is defined as the ability of the innate or adaptive 
immune response to prevent and clear M. tb infection instantly by killing of the bacilli 
(53). The clearance of M. tb infection has been shown in studies conducted for 
evaluation of the role of T cell adaptive immune response in clearance of M. tb, these 
studies indicate that individuals with interferon gamma release assay (IGRA) positive 
tests can regress to QFT negative test later and still test positive with the tuberculin 
skin test (TST) (53). Even though the understanding of the mechanisms involved 
during host immune response to M. tb is limited, studies suggest that enduring T cell 
immune responses may possibly be responsible for controlling the bacterial replication 
as well as prevention of disease reactivation and progression. 
According to some scholars (75,76), the immune response against M. tb infection can 
be summarised under four major response spectra, based on the host immune 
reaction to the organism, termed the innate immune response phase, the acquired 
immune response phase, the quiescent infection phase, active infection phase and 
then clinical disease. During innate immune response phase, macrophages residing 
at the alveoli ingest and often destroy the M. tb bacilli resulting in controlled infection 
with some non-replicating dormant bacteria. After 2-3 weeks post-infection, acquired 
T-cell immune response develops wherein antigen specific T cells are recruited and 
proliferate within the lesions after which they activate macrophages which eventually 
kills the intracellular M. tb.  In quiescent infection phase, the M.tb stops growing and 
the bacteria is controlled in a non-replicating dormant state. Lastly, the disease may 
progress to active infection with the immune system maintaining the bacterial 
replication at a subclinical level (46). The four major response spectra proposed for M. 
tb infection are illustrated in figure 1.3. 
 





Figure 1.3: Spectrum of tuberculosis infection. Source: Barry et al, 2009 (47). 
 
1.7 Active TB versus latent TB (LTBI) 
 
Latent TB infection is the M. tb infection phase that is characterised by the persistence 
of the bacterium in the host.  People with LTBI do not have any signs or symptoms of 
TB and they feel well and healthy. These people are not infectious and therefore 
cannot spread the M. tb to other people. About one third of the world’s population 
(about 2 billion people) is estimated to be infected with M. tb (LTBI).  Only about 5 to 
15% of people with LTBI are believed to progress to active TB if untreated in their 
lifetime (75, 76, and 77).  The factors that influence the progression from LTBI to active 
TB disease include HIV infection, smoking, alcohol and indoor air population. As there 
are no clinical signs or symptoms suggestive of LTBI, the term LTBI is an 
immunological definition, which describes the reactivity of the individual to M. tb 
antigens, thereby leading to a positive   TST or IGRA test. There is no gold standard 
test for diagnosing LTBI as discussed further in later sections of this chapter. 
 
 




1.7.1 The tuberculin skin test (TST) 
 
The TST is the oldest still currently in use for the diagnosis of M. tb infection/disease. 
Robert Koch first defined a reaction caused by a compound known as tuberculin after 
preparing liquid culture with tubercle bacilli in 1990, which was followed by the 
development of the first tuberculin skin test in 1908 (65). This test is often used in 
diagnosing LTBI in countries with a low TB burden. It is however not so useful in 
settings with a high TB burden since almost everyone is latently infected. The TST 
relies on the delayed type hypersensitivity immune response which occurs when the 
individual taking the test is infected with M. tb (68, 69). It requires the injection of a 
purified protein derivative (PPD) intradermally in the lower part of the arm followed by 
reading of the amount of induration present or absent 48 to 72 hours. Although highly 
sensitive for M. tb infection, TST can produce false positive results from people who 
have been previously vaccinated with Baccilus-Calmette Guerin (BCG), as well as 
people who are also infected with other non-tuberculous mycobacteria (NTM). 
Furthermore, TST require two day visits to the clinic and cannot distinguish active TB 
from latent TB. It is still being used in high burden but resource constrained settings 
to guide the clinical management of M. tb infection/disease in special populations 
including children and individuals who are HIV infected. It is also used to support the 
diagnosis of some extra pulmonary forms of TB which are extremely challenging to 
diagnose including intra-ocular, spinal and tuberculous meningitis (47, 79, and 80). 
 
1.7.2 Interferon gamma release assays (IGRAs) 
 
IGRAs are the latest and more accurate in vitro T cell blood tests for diagnosing TB 
infection. IGRAs rely on the immune response elicited by blood cells against M. tb 
antigens including culture filtrate protein 10 (CFP10), TB7.7 and early secretary 
antigenic targert-6 (ESAT6) antigens (82,124). These tests, like the TST work on the 
principle that individuals who have previously been exposed and infected by M. tb 
harbour pre-activated T cells in circulation in their blood stream (81-83). These T cells 
then respond rapidly after re-challenge with M. tb antigens in vitro in the case of 
IGRAs, leading to the production of the cytokine IFN-γ, which is detected in culture 




supernatants by an enzyme linked immunosorbent assay (ELISA) in the case of the 
QuantiFERON® TB Gold (QFT) (Qiagen Cellestis, Carnegie, Victoria, Australia) tests 
or enzyme linked immunospot assay as obtained with the T-SPOT.TB (Oxford 
Immunotec, Oxfordshire, Abington, UK). These tests mainly differ in the blood sample 
type they use and assay methods. The T-SPOT TB makes use of peripheral blood 
mononuclear cells (PBMCs) to detect the number of T lymphocytes producing IFN-ү 
using (ELISPOT) (70). Unlike T-SPOT TB, QFT uses whole blood to directly detect 
IFN-ү that is secreted into the culture supernatant using ELISA. Unlike TST which uses 
PPD antigen that is not specific for M. tb, the antigens used in IGRAs are coded by 
genes which are found at the region of difference 1 (RD1) of the M. tb genome.  This 
region is deleted in most NTMs but is present in organisms belonging to the M. tb 
complex. 
The first generation of the QFT test made use of PPD, just like the TST and was 
approved by the United States (US) food and drug administration (FDA) in 2001. Due 
to limitations that come with PPD and advancement in genomics, leading to the 
discovery of ESAT6 and CFP10, the QFT TB Gold test (done in 24 tissue culture 
plates) and the T SPOT TB tests were developed. Further improvements in IGRAs led 
to the introduction of the QFT In Tube in the mid-2000s’, this version making use of a 
third antigen known as TB 7.7 (Rv2654) (84).  The QuantiFERON® TB Gold Plus (QFT 
Plus) is the newest generation of the QFT test and was developed with the aim of 
improving sensitivity for diagnosing M. tb infection. Unlike the QFT In Tube which 
contained three tubes (nil, TB Ag and mitogen), the QFT Plus contains a second TB 
antigen tube (TB2) in addition to the antigen tube (TB1) which was being used in the 
previous QFT tests. Both the TB1 and TB2 tubes contain M. tb-complex associated 
antigen peptides from the CFP10 and ESAT 6 proteins, and not TB7.7 (71). The first 
antigen tube in the QFT Plus test, which originally contained peptides from three M. tb 
antigens (ESAT 6, CFP10 and TB 7.7) now only consists of peptides from CFP10 and 
ESAT6 (72). It is believed that the TB1 tube consists of long peptides which elicits  
CD4 T cell immune responses whereas the additional TB2 tube consists of both short 
and long peptides (also belonging to CFP10 and ESAT6) which elicit CD4 and CD8 T 
cell immune response (73). 
IGRAs offer improved specificity over the TST and require only a day visit to the health 
care centre. However, despite all the advances made in the development of these 




tests, they have several limitations like the TST, IGRAs cannot distinguish active TB 
from LTBI. Moreover, IGRAs are prone to false negative and indeterminate results in 
people with compromised immune systems such as HIV infected people and those 
with genetic immunocompromising disorders (85). 
 
1.8 Diagnosis of active tuberculosis 
 
TB is largely curable, but diagnosing the disease remains a major challenge 
worldwide. This is because of the lack of diagnostic tests which are sensitive, specific, 
rapid and implementable worldwide, including in resource-poor areas. (54). Many of 
the tests that are currently available have similar limitations including poor 
performance in some patient groups including people who are co-infected with HIV,  
people with extrapulmonary TB and young children due to either paucibacillary 
disease or difficulties in obtaining good quality samples, including the lack of expertise 
in collecting relatively invasive samples such as gastric aspirates. In this part of the 
current chapter, we will briefly discuss the main diagnostic tests that are routinely used 
in the diagnosis of active disease, followed by a brief look at relatively newer 
approaches (85). 
 
1.8.1 Clinical diagnosis of TB disease 
 
Empirically diagnosis is common in the management of TB, mostly owing to the non-
availability of diagnostic tests. This is mostly done through the interrogation of 
symptoms and signs shown by the patient at presentation at the health care centre. 
TB symptoms include fever, night sweats, weight loss and cough >2 to 3 weeks, as 
well as lymphadenopathy. However, because TB symptoms are the same as the 
symptoms experience by people suffering from other conditions, empirical diagnosis 
often leads to over-diagnosis, which results in unnecessary chemotherapy and 
wastage of resources with another consequence being patients suffering with 
unnecessary side effects. The consequences are even grave for patients suffering 
from extra pulmonary TB as the symptoms will be confused with other conditions, for 




example, pleural TB being mistaken for cancer or spinal TB being mistaken for other 
spinal anomalies. 
 
1.8.2 Radiological diagnosis of TB disease 
 
Chest X-rays are routinely used as a principal test for radiological assessment of 
suspected as well as proven TB cases. Individuals who present at the primary health 
clinics with symptoms such as weight loss, unexplained chronic fever and persistent 
cough lasting for more than 2 weeks are often evaluated for TB using a chest X-ray 
(54). This technique therefore allows imaging of the consolidation or infiltrates which 
are often found in the upper lungs with or without hilar lymphadenopathy although they 
can also appear at any place in the lungs (55-57). This diagnostic tool provides 
important information regarding follow up and management of patients which can also 
be useful in treatment monitoring purposes. Although useful, chest X-rays are not 
specific for pulmonary TB diagnosis since they may look normal when disease is 
actually present (58, 59). In addition to chest X-ray, computed tomography (CT) is also 
used to define unclear lesions as well as detecting fine lesions which may have been 
missed during chest X-ray visualisation (58, 60). Moreover, when plain films are 
inconclusive or normal, chest CT is considered as a useful diagnostic method which 
provides important information on how to manage the ill health. This test can therefore 
provide useful leads in detecting bacterial activity. The main limitation of the use of 
chest X-rays is that radiological facilities are not available at lower levels of the health 
care system. In many countries, e.g., most of Sub-Saharan Africa, patients have to 
travel for long distances in order to access X-ray facilities. X-rays are also not readily 
affordable, which is another limitation. Positron emission tomography-computed 
tomography (PET-CT) offers an advanced nuclear medicine imaging diagnostic 
technique by combining PET scanner and X-ray CT scanner in a single gantry in order 
to acquire subsequent images obtainable from both devices at the same time allowing 
the combination of two devices to produce superposed image. PET-CT may be a 
useful tool especially as a tool for monitoring the response to TB treatment as 
demonstrated in the study by Malherbe et al (74). However, implementation of PET 




CT in the management of TB, even at referral hospitals is not feasible due to high 




Smear microscopy is recommended by the WHO as a standard TB diagnostic test and 
is relatively rapid, simple, specific and inexpensive. Conventional light microscopy of 
Ziehl-Neelsen-stained smears that are prepared directly from sputum to detect acid 
fast bacilli (AFB) is the most widely TB diagnostic test in resource limited settings (86). 
The main limitation of smear microscopy is poor sensitivity as mycobacteria are 
required to be present in the specimen at a concentration of 5000 to 10 000 organisms 
per millilitre for a positive result to be obtained (87). The main sample type that is used 
for smear microscopy (sputum) is difficult to obtain in some patient groups especially 
children, whereas, sputum may be useless if TB is extrapulmonary as briefly 
mentioned previously. Because of the low numbers of bacilli that are present in other 
biological fluids, the yield from other extrapulmonary samples is often poor.  Moreover, 
it is not possible to distinguish between live and dead bacilli using microscopy and the 
technique is unable to identify drug resistant M. tb strains (61). However, fluorescent 
microscopy has been shown to be 10% more sensitive than Zielh-Nelsen test (61). 
 
1.8.4 Mycobacterium tuberculosis culture 
 
Despite ongoing research and resultant improvements in diagnostic tools for TB, M. 
tb culture remains the only WHO recommended gold standard for diagnosing active 
TB (88). Cultures are not only used to confirm the presence of M. tb but also to obtain 
information about important drug susceptibility testing (62, 63). Culturing of M. tb is 
done either on solid media (Lowenstein-Jensen method) or liquid media, for example, 
as done in the mycobacterial growth indicator (MGIT) tubes (Becton Dickenson). Solid 
cultures are known to be very slow. In comparison, liquid cultures yield results within 
2-4 weeks. However, it still takes up to 42 days before negative culture results are 
confirmed, owing to the slow growing nature of M. tb, with the time taken for results to 
be positive largely depending on the bacterial load in the specimen (e.g., sputum 




sample). Despite the limitation of the long turn-around time, culture remains the most 
sensitive method for the diagnosis of TB disease, as it requires bacilli at the 
concentration of 10 per ml of specimen for positive results to be obtained. Other 
limitations of culture include prone to contamination, costs and the requirement of 
biosafety level 3 environment and highly skilled staff. Because of these limitations, 
culture facilities are not widely available, with some countries only having a single 
laboratory that is capable of doing cultures, with most of these laboratories being 
owned by international organisations such as the Pasteur Institute, Biemerieux 
amongst others (64). As with smear microscopy, the reliance on a good quality sputum 
sample is a limitation, meaning that patient groups that cannot provide samples for 
microscopy as highlighted in the previous section will not also be able to provide 
samples for culture. 
 
1.8.5 Nucleic acid amplification and molecular beacon-based tests 
 
Nucleic acid amplification tests (NAATs) allow the detection of M. tb DNA using PCR 
or transcription mediated amplification. These heterogeneous tests differ in terms of 
accuracy and the nucleic acid sequence detected. The most commonly available tests 
are Amplicor Mycobacterium tuberculosis test (Roche diagnostics) which amplifies 
19s ribosomal ribonucleic (RNA) gene region and mycobacterium direct test (MTD, 
Gen-Probe) which is based on reverse transcription M. tb-specific ribosomal 
ribonucleic acid (rRNA) targets. Furthermore, these tests have been studied and found 
to be more accurate when performed using respiratory samples instead of other 
specimens (65). NAATs are mostly used for diagnosis of TB on clinical specimens 
such as cerebrospinal fluid (CSF), sputum and lymph node aspirates, they are also 
useful as confirmatory TB testing by rapidly detecting M. tb in 50-80% of AFB smear 
negative and culture positive specimens. Furthermore, NAATs are also intended for 
diagnosis of drug resistance as a follow-up to culture positive results. Although these 
tests provide high sensitivity and specificity, yield results within approximately 3 hours, 
these tests are prone to false positive results since they do not detect viable bacteria 
which rule them out from monitoring TB treatment, they are also expensive and are 
not available in all settings. 




One of the most important recent advancements in the field of TB diagnostics has 
been the development of the molecular beacon-based assay; the GeneXpert MTB/RIF 
test (Cepheid, Sunnyvale, USA). In addition to detecting M. tb DNA in a closed 
cartridge based system, the test also detects resistance to rifampicin which provide an 
indication for multidrug resistance, and yields results within two hours (66). Recent 
systematic review and meta-analysis studies showed that the sensitivity of the Xpert 
test is 94.4% with a pooled specificity of 98.3%. Recently, a new version of the test 
(the GeneXpert Ultra) was introduced. While the detection threshold of the standard 
Xpert tests is about 100 bacilli per millilitre of sample, Xpert Ultra reportedly has a 
higher sensitivity as it is reportedly capable of detecting bacilli with the same sensitivity 
as culture (89-90, 96). However, this test is highly expensive and its maintenance also 
costly (87, 91). 
 
1.8.6 Immunological diagnostic tests for active TB 
 
In addition to the TST and IGRAs, which are mainly M. tb infection diagnostic tests as 
discussed above, serological tests were the only alternative immunological tests that 
were used for the diagnosis of active TB. Although, such tests have been used for a 
long time (92, 93) the WHO published a negative recommendation, banning the use 
of all the then commercially available serological tests for the diagnosis of TB (94). 
Despite this ban, much research has been ongoing on the development of newer and 
improved versions of the tests since serological tests are rapid, relatively cheap and 
easily implemented as point-of-care diagnostic tests. In recent studies, making use of 
recently characterised M. tb antigens and investigating multiple classes of antibodies 
against these antigens, results have been very promising (95). These raise the hope 
for the future development of newer versions of serological tests, but although there 
are companies currently manufacturing such tests e. g Lionex Diagnostics and 
Therapeutics, Braunsweig, Germany, WHO approved commercially available 
serological tests do not currently exist (97). Other immunological diagnostic 
approaches have been investigated solely for research purposes (as discussed below) 
with no commercial tests currently available. 
 
 




1.9 The use of host immunological biomarkers in the diagnosis of TB 
 
In search of tools that will enable the earlier and more rapid diagnosis of TB disease, 
in all study participants including people living in resource-poor communities, scientists 
have been looking at immunological host biomarker-based approaches as possible 
candidate tools for the diagnosis of TB disease. According to the WHO target product 
profiles (TPP) published in 2014 (97), two of the four key diagnostic tests that are 
needed for combatting TB in the sustainable development goals era are a non-sputum 
biomarker based test that is capable of diagnosing TB disease including pulmonary 
and extrapulmonary TB, in all patient types including children, and a non-sputum triage 
test that is capable of being implemented for the diagnosis of TB disease at point-of-
care in community health centres (97). Immunological tests are particularly very 
attractive and likely to fulfil these criteria because they are easily converted into point-
of-care diagnostic tests, e.g., using the lateral flow technology as recently 
demonstrated (98, 99). 
Faced with the reality that IGRAs are not useful in the diagnosis of TB in high burden 
settings (100) researchers including those in our research group started investigating 
new host biomarkers, other than IFN-γ and new antigens, other than those used in 
IGRAs (ESAT6 and CFP10) and which could enable the diagnosis of active TB. 
Studies evaluating the potential of biomarkers that are detectable in QFT supernatants 
revealed that multiple biomarkers detectable in QFT In Tube supernatants possessed 
diagnostic potential for active TB (100, 101, 102), whereas other studies showed that 
the use of new antigens other than ESAT6 and CFP10 (103, 104) and evaluation of 
biomarkers produced by these antigens (105) also showed potential in the diagnosis 
of TB. Given that diagnostic tests based on host biomarkers detected in overnight 
culture supernatants will only yield results within 24 hours, researchers have been 
evaluating ex vivo host biomarkers. Therefore studies evaluating host biomarkers 
detected in relatively easily collected sample types such as saliva (106, 107), urine 
(108) and also sputum biomarkers (109) and biomarkers detectable in other 
extrapulmonary fluids including pleural fluid (110,111) and cerebrospinal fluid (111) 
amongst others have been done. All these studies identified various biosignatures 
which showed potential as diagnostic tools for TB disease and investigations on some 
of these biosignatures are currently ongoing, in the Stellenbosch University 




Immunology Research Group (SU-IRG) laboratories and other partner institutions.  
Concerning possible point-of-care applicability, blood-based biomarkers are currently 
the closest to development into diagnostic tests. Previous studies done at the SU-IRG 
in collaboration with partners situated in other countries identified host immunological 
biomarkers that are detectable in serum and plasma and which showed strong 
potential as a screening test for TB (negative predictive value >90% (111,112) . A 
point-of-care test, based on the up-converting phosphor imaging lateral flow 
technology (employed in (98, 99) is currently under development in a multi-institutional 
project involving five African countries in collaboration with European partners 
(www.screen-tb.eu). Host transcriptomic biosignatures have also shown potential as 
tools for the diagnosis of TB in both adults (115, 115) and children (116). Although, 
based on flow cytometry and so will probably be difficult to implement at the point of 
care, the T cell activation marker tuberculosis (TAM-TB) assay (118) is another 
recently developed test which showed potential in the diagnosis of TB disease, with 
further evaluations of the platform currently ongoing. 
Although the biosignatures discussed in the previous paragraph have shown potential 
in the diagnosis of active TB, there are as yet no commercially available tests that 
make use of host biomarkers. Of more relevance to the work done in the current thesis 
is previous work that evaluated the usefulness of host biomarkers detected in QFT In 
Tube supernatants as diagnostic biosignatures for TB disease. One of the key such 
studies (102), identified 3-marker cytokine signatures in QFT supernatants which 
diagnosed TB disease in a case-control study with accuracy >90%. Such 
biosignatures were also shown to possess diagnostic potential in children (118) and 
adults in other studies (100, 101). Although assays based on stimulation of whole 
blood with TB antigens, followed by detection of host immunological biomarkers will 
only yield results in about 24 hours, such assays may be useful (when compared to 
assays making use of unprocessed, ex vivo samples) in individuals with difficult-to-
diagnose TB disease such as those with extra pulmonary TB and children and they 
may be more specific to M. tb. 
As discussed above, the QFT Plus is a recently introduced test for the diagnosis of M. 
tb infection. According to the manufacturer, the test has a sensitivity >95% for M. tb 
infection and is therefore more accurate than the previous generation (QFT In Tube) 
on which most of the studies discussed above were based. As there have been not 




many independent evaluations of the test, it is imperative that the utility of the assay 
be evaluated in different study settings, including high burden settings such as 
obtained in Cape Town, South Africa. If the QFT Plus is indeed as sensitive and 
specific as claimed by the manufacturer, the test in combination with symptoms and 
signs may assist in the diagnosis of active TB. Furthermore, the host biomarkers that 
showed potential in QFT In Tube culture supernatants might perform better when 
assessed in QFT Plus supernatants. Therefore, the focus of the present thesis shall 
be the assessment of the accuracy of the QFT Plus test in patients that were 
suspected of having active TB and enrolled into a large, multi-institutional diagnostic 
trial (the screen-TB project), and assessment of biomarkers that previously showed 
potential in QFT In Tube supernatants, and recently described candidates as 
diagnostic tools for active TB. If promising, findings from the project will inform the 
planning of future larger, including studies focusing on the traditionally difficult-to-
diagnose TB types such as childhood and extrapulmonary TB as mentioned in the 
previous paragraphs that are conducted in multiple field sites, to determine the 
diagnostic value of the biosignatures from the project in programmatic settings. 
 
1.10 Study hypothesis 
 
The QFT Plus test will be useful in the diagnosis of active TB, when used in 
combination with symptoms, in individuals suspected of having pulmonary TB, in 
comparison to a composite reference standard. Furthermore, as the test is a newer 
and improved version of the QFT In Tube, host biomarkers detected in supernatants 
from QFT Plus tubes shall be useful in the diagnosis of active TB, when compared to 
findings from the QFT In Tube system that are in the literature. 
 
1.11 Study aims 
 
1.11.1 To evaluate the usefulness of the QFT Plus test when used in combination with 
symptoms, as a tool for the diagnosis of TB disease in people suspected of having 
active TB in a high burden setting 




1.11.2 To evaluate host biomarkers detected in QFT Plus supernatants as 
biosignatures for the diagnosis of active TB 
 
Study specific objectives 
 
1. To evaluate the utility for the QFT Plus test, including the use of different cut-off 
values in the diagnosis of active TB 
2. To evaluate the usefulness of the QFT Plus test when used in combination with 
symptoms as a tool for the diagnosis of active TB 
3. To evaluate the usefulness of host biomarkers, including analytes previously 
described in QFT In Tube supernatants and new host markers as diagnostic 
candidates for the diagnosis of active TB 
4. To evaluate usefulness of combinations between host markers elicited after 
stimulation with QFT Plus TB1 and TB2 antigens, and unstimulated culture 
supernatants in the diagnosis of active TB 
5. To evaluate the differential expression of host biomarkers detected in QFT Plus 
supernatants in patients with TB disease, individuals with LTBI and those without 














Materials and methods 
 
2.1 Study participants and setting 
Participants included in the present study were recruited from primary health care 
clinics in urban areas of Cape Town, South Africa including Adriannse and 
Fisantekraal. All study participants were recruited between November 2016 and 
October 2017. These participants formed part of a larger ongoing biomarker project 
known as the ‘ScreenTB’ study (www.screen-tb.eu), whose main focus was the 
development and evaluation of a point-of-care, screening test for active TB disease in 
finger-prick blood samples. The main study is a collaboration between Stellenbosch 
University and institutions in other African institutions with the other African partners 
being based in Namibia, The Gambia, Uganda, Ethiopia, and the European partners 
being Leiden University in the Netherlands and the London School of Hygiene and 
Tropical Medicine in United Kingdom. Study participants enrolled in to the study were 
individuals presenting with signs and symptoms requiring investigation for TB disease 
and were recruited if they met the study’s inclusion criteria. Recruitment of study 
participants for the main ScreenTB project is still ongoing. 
 
2.1.1 Inclusion criteria 
 
To be eligible for inclusion in the study, the study participants had to be willing to give 
written informed consent and undergo HIV testing or disclose their HIV positive status 
to the study nurses. Participants had to be between the ages of 18 and 70 years, and 
have been coughing for more than two weeks in addition to having at least one other 
TB suggestive symptom or sign such as fever, weight loss, haemoptysis,  malaise, 








2.1.2 Exclusion criteria 
 
Participants were excluded from the study if: 
 They were on TB treatment or had received treatment in the previous 90 days. 
 They were HIV positive and on isoniazid (INH) prophylaxis. 
 They had no permanent address and had not been living in the community 
where the study was being conducted for up to 3 months. 
 They were pregnant or breast feeding. 
 Their HB was greater than 9 g/l 
 They had been treated with quinolone or aminoglycoside antibiotics in the 
previous 60 days. 
 
2.1.3 Ethics statement 
 
As mentioned in 2.1, the study was a sub-study of the ScreenTB project. The 
ScreenTB study (including these sub-studies) was approved by the Health Research 
Ethics Committee of the Faculty of Medicine and Health Sciences of the University of 
Stellenbosch (N16/05/070), and also the City of Cape Town. 
 
2.2 Sample collection  
 
After written informed consent blood, sputum and other samples required for the main 
ScreenTB project were collected from all study participants, and prior to the 
establishment of the diagnosis of TB or no-TB disease (Figure 2.1).  About 1mL of 
whole blood (WHB) was collected by venepuncture directly into QuantiFERON Plus 
(QFT-Plus) tubes after which the tubes were transported at ambient conditions to the 
Stellenbosch University Immunology Research Group (SU-IRG) laboratory for further 
processing. Upon arrival in the laboratory, the QFT Plus tubes were incubated 
overnight (18 to 24 hours) at 37 °C, in a 5% CO2 incubator after which culture 
supernatants and sediments were harvested and further processed as described 
below. Sputum samples collected from the study participants were used for 




microbiological diagnosis, which formed part of the algorithm for diagnosing TB 
disease as discussed below. 
 
2.2.1 Reference standard used in the classification of study participants as TB 
or other respiratory diseases 
 
Sputum samples collected from study participants were processed and microbiological 
tests done as these tests formed part of the classification algorithm which made up 
the composite reference standard. Sputum samples collected from all participants 
were used for smear microscopy using Ziehl–Neelsen test, GeneXpert and culture 
using the Mycobacteria Growth Inhibitor Tube (MGIT) method. MGIT cultures which 
were positive were checked for contamination by the examination of Ziehl-Neelsen 
stained smears for acid fast bacilli. This was then followed by confirmation of 
organisms of the MTB complex using Capilia TB testing (TAUNS, Numazu, Japan).  
As was done in previous studies (101,114), study participants were classified as either 
definite TB, probable TB or other respiratory diseases (ORD) using a combination of 
clinical, laboratory and radiological findings (Table 2.1). Similarly, participants 
classified as ORD had a variety of other diagnosis which included upper and lower 
respiratory tract infections, and acute exacerbations of chronic obstructive pulmonary 
diseases or asthma as described in (101,114). However, bacterial and viral cultures 
were not performed to identify these organisms as the main ScreenTB project was not 
funded to do these detailed diagnoses.   
As mentioned above (section 2.1) recruitment of study participants into the ScreenTB 
project is currently ongoing. For the purposes of the current study, we only analysed 
samples from individuals that were recruited from the beginning of the study 
(11/10/2016) and (19/10/2017). Samples collected from study participants enrolled 
during this period were processed using all the techniques described in the present 
dissertation, for the purposes of my MSc project. 
 
 








Figure 2.1: STARD flow diagram showing the study design and classification of 
participants. *These study participants were excluded either because they had culture 
contamination in addition to having negative sputum smear results (n=8) or because 
no final decision was arrived at as to whether they were TB patients or individuals with 
ORD as a result of missed week 2 and/or month 2 visits (n=8). TB= pulmonary 
tuberculosis, ORD= other respiratory diseases; that is, patients in whom TB disease 











Table 2.1: Summary of algorithm used in classification of ScreenTB participants. 
All participants enrolled had respiratory symptoms compatible with active TB 
Classification  Definition  
Definite TB 
Positive sputum Culture  
      OR 
Positive GeneXpert (and no previous TB episode in past year)       
 
Probable TB 
AFB smear result positive and CXR compatible with TB 
OR 
AFB smear result positive and initiated on TB treatment with good 
treatment response 
OR 
CXR results compatible with TB and initiated on TB treatment and 
shows good response 
OR 




Not initiated on TB treatment and symptom resolution or other 
diagnosis was made 
OR 
CXR signs compatible with TB but not initiated on TB treatment and 
resolution of symptoms or other diagnosis made 
Exclude from 
analysis 
Not able to assign category due to: 
crucial data missing in the form of sputa results (not done or 
contaminated), or CXR (not done) 
OR 
CXR signs compatible with TB and initiated on TB treatment, but 
participant’s symptoms show doubtful response on treatment 
OR 




Loss to follow up and treatment response not evaluated 
This diagnostic algorithm (previously published in (133)) is the same algorithm that 
was employed in the current study. 
 
2.2.2 Processing of QFT Plus supernatants and sediments 
2.2.2.1 QFT Plus supernatants 
 
The QFT Plus tubes were centrifuged at 3000 x g for 15 minutes to separate the 
plasma from the blood. The plasma from each of the tubes was aliquoted and stored 
in micro centrifuge tubes as follows: 150 µL of plasma was added to the first two tubes 
and the remainder into the third tube. All tubes were then frozen at -80°C until used 
for IFN-γ measurement or the Luminex platform as described below. 
 
2.3 QuantiFERON-TB® Gold Plus Enzyme Linked Immunosorbent Assay (ELISA) 
2.3.1 Principle of the QuantiFERON-TB® Gold Plus ELISA 
 
ELISA is a biological technique which is mainly used in immunological assays to detect 
and quantify antibodies or antigens of interest. QFT Plus ELISA was used to detect 
IFN-γ concentrations in order to diagnose M. tb infection in the current study 
participants. The QuantiFERON Plus tubes contain a negative and positive control. 
The mitogen tube acts as a positive control and addresses the immune competence 
of the participant’s immune cells. More importantly, it serves as a control for proper 
sample transport, blood handling and incubation. A positive IFN-γ response is 
considered when either TB antigens response is significantly above Nil IFN-γ value 
(≥0.35 IU/ml). When a blood sample has a negative response to the TB antigens and 
a low response to Mitogen, the results is considered indeterminate. According to the 
manufacturer, such a result may occur due to incorrect filling or mixing of Mitogen 
tube, or the inability of the patient’s lymphocytes to produce IFN-γ. The Nil tube serves 
as a negative control which adjusts for the background and therefore has to be 
subtracted from the IFN-γ levels of TB antigen and mitogen tubes. 
 




2.3.2 QFT TB® Gold Plus ELISA procedure  
 
IFN-γ concentrations in QuantiFERON supernatants were determined using 
QuantiFERON TB® Gold Plus ELISA kit. One hour before starting the ELISA all plasma 
was thawed and reagents except the 100x concentrate conjugate were brought to 
room temperature (22°C ± 5°C). Each plate contains a standard dilution in duplicates, 
a laboratory generated internal control (IntCtr) in triplicates and up to 21 plasma 
samples. The IFN-γ standard was reconstituted with the volume of distilled water 
indicated on the label of the IFN-γ Standard vial. The reconstituted standard was then 
mixed gently to minimize frothing and to ensure complete solubilisation. The 
reconstituted kit standard was the diluted 1:2 to reach a concentration of 2 IU/mL for 
Standard 1 followed by a 1:4 dilution series to reach concentrations of 1 IU/mL and 
0.25 IU/mL for standard 2 and standard 3 respectively.  
After preparing the standard dilution series, 100x concentrate conjugate was 
reconstituted with 300µL distilled water and mixed until dissolved completely. A 
working solution was prepared by pipetting 60μL of reconstituted Conjugate 100x 
Concentrate into 6.0mL of ‘Green Diluent’. 50 µL of the freshly prepared working 
solution was added to all the wells using a multichannel pipet. 50 µL of the plasma 
sample, internal control (IntCtrl) and lastly Standard dilution was added to the 
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Figure 2.2: QFT Plus ELISA plate layout. S1= Standard 1, S2= Standard 2, S3= 
Standard 3, S4= Standard 4, Nil= Control plasma, M= Mitogen plasma, TB1= M. tb 
specific antigen 1, TB2=M. tb specific antigen 2.  
 
 
All plates were gently shaken by hand to mix, followed by incubation at room 
temperature (22 ̊C ± 5°C) for 2 hours. Wash Buffer 20x Concentrate was diluted 1:20 
with distilled water. Following incubation, plate wells were washed with 1x Wash Buffer 
by hand, whereby each well was filled to the top of the well. The washing step was 
repeated 10 times. After adding 100µL of enzyme substrate solution to each well, the 
plate was carefully tapped on the sides and incubated for 30 minutes at room 
temperature (22°C ± 5°C). After 30 minutes incubation, 50µL Enzyme stopping 
solution was added to each well and mixed thoroughly. The addition of stop solution 
was done in the same order and at approximately the same speed as the Enzyme 
substrate addition step. Within 5 minutes, the optimal density was measured in each 
well using a microplate reader fitted with a 450 nm filter and 620 nm to 650nm 




reference filter.  The raw data were imported into the QFT-Plus Analysis Software, to 
generate a standard curve which has to be validated before results can be taken. The 
following criteria have to be met for an ELISA run to be valid (taken from QuantiFERON 
handbook): 
 The mean OD value for Standard 1 must be ≥0.600. 
 The %CV for Standard 1 and Standard 2 replicate OD values must be ≤15%. 
 Replicate OD values for Standard 3 and Standard 4 must not vary by more than 
0.040 optical density units from their mean. 
 The correlation coefficient (r) calculated from the mean absorbance values of 
the standards must be ≥0.98. 
 
QFT-Plus results are interpreted using the criteria in table 2.2 
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2.4  Luminex multiplex immunoassay 
 
The Luminex multiplex immunoassay platform was used for evaluation of the 
concentration of host immunological biomarkers in QFT Plus supernatants in the 
current project. 
 
2.4.1 Principle of Luminex assay 
 
The Luminex multiplex assay is an assay which is used to measure multiple analytes 
concurrently in a single well of a microtiter plate. The sample is added to a mixture of 
colour-coded beads which are pre-coated with analyte specific capture antibodies that 
binds to the analytes of interest.  The biotinylated detection antibodies specific to the 
analytes of interest are added and form an antibody-antigen sandwich. This is followed 
by adding Phycoerythrin (PE)-conjugated streptavidin which binds to the biotinylated 
detection antibodies.  The Luminex 200 platform and Flex Map 3D system, dual-laser 
flow based detections instrument, are used to read the polystyrene beads. The first 
laser is a 635nm red laser (classification laser) which segregates the beads and 
determines the analytes by exciting the dyes inside the beads. The second laser is 
532nm green laser (reporter laser) which excites the PE. A high-sensitivity 
photomultiplier tube (PMT) detector detects the emission of PE, which is directly 
proportional to the amount of analyte bound.   
The Luminex MAGPIX® is another instrument which can be used in reading the results 
of Luminex multiplex experiments. Unlike the Luminex 200 instruments, the Magpix 
only uses magnetic and not polystyrene beads. The analyser makes use of a magnet 




which captures and holds the magnetic beads in a single layer. The instrument 
consists of two spectrally different light-emitting diodes (LEDs), the 525nm green LED 
and 635nm red LED, which illuminate the beads. The red LED is used to identify the 
beads to which analytes are bound based on their fluorescent patterns.  The green 
LED is used to read the PE derived signal if the analyte of interest is present in the 
sample. The software used in the instrument then processes all images and 
determines the concentration of the analytes based on a standard curve. The main 
difference between these instruments is that the Flex Map 3D can read up to 500 
analytes, the Luminex 200 up to 100, and Magpix up to 50 analytes. Figure 2.3 
illustrates the principle of the luminex assay. 
 
 
Figure 2.3: Principle of Luminex illustration. Source: miltenybiotec.com 
For the reagent kits employed in the present project, all the detection antibodies were 
biotinylated, with the detection reagent being streptavidin-phycoerithrin. 





2.4.2 Luminex assay procedure 
 
Luminex assays were performed following the instructions of the manufacturers of the 
reagent kits used. All reagents used in the current project were purchased from Merck 
Millipore (Billerica, MA, USA) and R&D systems (Biotechne, Minneapolis, MN, USA).  
We evaluated the concentrations of 37 analytes in QFT Plus nil, TB1 and TB2 antigen-
stimulated supernatants from all study participants. All samples and reagents were 
brought to room temperature prior to the start of experiments. After thawing, samples 
were vortexed and centrifuged for 3 min at 3000xg followed by preparations of all 
reagents, standards and quality controls as directed by the manufacturers. The 
Luminex plates were pre-wetted with appropriate wash buffer and incubated on a 
shaker for 10 minutes (if recommended by the manufacturer) followed by the addition 
of standards and the controls from the manufacturer if available with the kit being 
evaluated. For the Milliplex assays, a serum matrix solution was added to the 
standards and controls wells, followed by addition of samples to the appropriate wells. 
Mixed beads were added to each well and the plate was incubated for 2 hours at room 
temperature or overnight at 4 degrees Celsius on a plate shaker, following the speed 
recommended by the kit manufacturers. Following the incubation, all plates were 
washed using the respective wash buffers as recommended by the manufacturers in 
the kit inserts. Detection antibodies were then added to each well followed by 1 hour 
incubation. The plates were then washed again, followed by addition of Streptavidin-
Phycoerythrin and incubated for 30 minutes. This was then followed by a further wash 
step,  resuspension in either Sheath or Drive fluid and then reading on a Bio-Plex 200 
instrument (Bio-Rad laboratories, Hercules, CA, USA ) and or MAGPIX (Bio-Rad 
laboratories). Bead acquisition and analysis of median fluorescence intensity were 
done using the Bio-Plex ManagerTM version 6.1 software (for plates read on the Bio- 
Plex 200 instrument) or the Bio-Plex MP software, followed by Bio-Plex Manager 6.1, 
if the Magpix instrument was used. All samples were analysed in a blinded manner. 
Host biomarkers evaluated in the study are listed in table 2.3. Prior to analysis, 
samples were pre-diluted as shown in table 2.4.  
 




Table 2.3: List of Luminex kits and analytes employed in the study  
 Luminex kits  Analytes  
Reagent kit catalogue numbers and analytes purchased from Merck Millipore 
Human Neurodegenerative disease 
magnetic bead panel 1 
HNDG1MAG-36 K 
Interleukin 4 (L-4), IL-6, Macrophage 
inflammatory protein 1-apha (MIP)1-α , -
interferon alpha 2 (IFN)-α2 
Human Neurodegenerative disease 
magnetic bead panel 1 
HNDG1MAG-36 K 
Complement C3  
Human Neurodegenerative disease 
magnetic bead panel 2 
HNDG2MAG-36 K 
 Complement C4 
Human Cytokine/Chemokine 
Magnetic  Bead Panel 
HCYTOMAG-60K 
Apolipoprotein A1, Apolipoprotein CIII, 
Complement Factor H 
Human Cardiovascular Disease 
HCVD2MAG-67K 
D-dimer, GDF-15,Myoglobin, MPO, NGAL, 
sVCAM-1,  
Human Neurodegenerative disease 
magnetic bead panel 3 
HNDG3MAG-36 K 
BDNF,  Cathedpsin -D, ICAM-1, MPO, PDGF-
AA, RANTES,PDGF-AA/BB, VCAM-1, PAI 1 
Human complement  
HCMP1MAG-19K 
Complement C2, Complement C5, 
Complement C4b, Complement 5a, 
Complement C9, Complement factor 1, MBL 
 
Reagent kit catalogue numbers and analytes purchased from R&D systems  
R&D LXSAHM-02 NCAM-1/CD56, TGF-α 
R&D LXSAHM-02 Ferritin, MMP-9 
R&D LXSAHM-08 
CXCL9/MIG,EGF, P-Selectin, LIGHT, IL-3, 
CCL/MCP-2, IL-15, VEGF 
R&D LXSAHM-20 
ADAMTS13, CCL2/MCP-1, CD40 Ligand, 
CXCL11/ITAC-1, Fas, IFN-γ, IL-beta, IL-13, 
IL-2, IL-33, CCL1/I-309, CCL4/MIP-1, 




CXCL10/IP, CXCL8/IL-8, GM-CSF, IL-1 
alpha, IL-10, IL-1 rα, IL-22, TNF-alpha 
 
Table 2.4: Dilution of samples prior to use in the Luminex experiments. All dilution 
factors used were as prescribed by the reagent kit manufacturers. 
Kits Dilution factors 
HCVD2MAG-67K 1:100 dilution 
HNDG1MAG-60K Neat sample 
HNDG1MAG-36K 1:40,000 Dilution 
HCMP1MAG-19K 1:2 Dilution 
LXSAHM-02 1:2 Dilution 
LXSAHM-08 1:2 Dilution 
LXSAHM-20 1:2 Dilution 
 
2.3 Statistical analysis 
 
All statistical analysis was performed using Graph Pad Prism version 7.04 (San Diego, 
CA, USA) and Statistica (TIBCO Software Inc, CA, USA). The Mann-Whitney U-test 
was used for the evaluation of differences in the concentrations of individual host 
biomarkers between any two groups e.g. TB vs. ORD. The diagnostic accuracy of 
individual biomarkers was evaluated by receiver operator characteristics (ROC) curve 
analysis. Cut-off values and associated sensitivity and specificity were determined 
using Youden’s Index. The General discriminant analysis (GDA) procedure was used 
to assess the predictive abilities of combinations between multiple host biomarkers. 
Prediction accuracy was ascertained by leave-one-out cross validation. P-values ≤ 








2.4  Role of the candidate in the project 
 
After joining the research group in February 2017, processing of all QFT Plus samples 
for the main ScreenTB project and the extra steps done as part of the Candidate’s 
project were done by the candidate. All the QFT Plus ELISA experiments were 
performed by the candidate and results quality controlled by experienced laboratory 
staff and imported into the main ScreenTB data base for use by the consortium. The 
candidate also performed all the Luminex experiments (with assistance of research 
assistants), cleaned all data in preparation for analysis, analysed the data with help 
from the Centre for Statistical Consultation of Stellenbosch University (Professor 
Martin Kidd) especially on the diagnostic biomarker models, and wrote the thesis. I 
have also been responsible for writing a draft manuscript on the results as well as 


















Evaluation of the potential usefulness of the QuantiFERON® TB Gold Plus test 
as a tool for adjunctive diagnosis of TB disease 
3.1 Introduction 
  
TB continues to be one of the leading causes of death worldwide and resulted in the 
deaths of an estimated 1.3 million adults, with 10 million reportedly falling ill with the 
disease in 2016 (6). As also discussed in chapter 1, Interferon gamma release assays 
(IGRAs) and the tuberculin skin test (TST) remain the only approved immunological 
diagnostic tests for TB. These tests are generally not recommended for the diagnosis 
of active TB disease, especially in high burden settings, such as obtained in South 
Africa, because of the high prevalence of latent M. tb infection (119). However, positive 
IGRA or TST results do lead at least, to preventative treatment with isoniazid in some 
patient groups, including children under the age of 5 years, HIV infected individuals 
and those undergoing immunosuppressive therapy (120, 121). In the case of the 
diagnosis of some particularly difficult-to-diagnose extra pulmonary TB types such as 
ocular TB and TB meningitis, these tests form part of the diagnostic algorithms that 
are employed in ruling-in or ruling-out TB, in the course of differential diagnosis. 
As discussed in chapter 1, the QuantiFERON® TB Gold (QFT) Plus test is a new 
generation of IGRA that was introduced for the management of TB recently (122) and 
replaced the QFT In Tube. After the introduction of the QFT In Tube to the market in 
the mid-2000’s, several investigations were done, aimed at determining whether  the 
test could contribute to the diagnosis of active TB, leading to the recommendations 
against the use of the test in high burden settings (123). As the QFT Plus is a new 
test, without much independently published data about its use currently available, and 
with the manufacturer claiming that it is more sensitive than the QFT In Tube (>94% 
sensitivity for M. tb in individuals with active TB disease depending on the extant of 
TB disease and the TB settings), we sought to evaluate the accuracy of the test in the 
diagnosis of active TB disease in patients with suspected TB and to investigate 
whether the use of the test, in conjunction with symptoms has the potential to make 
any contribution to the diagnosis of active TB in a high burden setting. Knowledge 




gained may contribute to further research on the potential use of the test in the 
management of TB in the difficult-to-diagnose TB types (paediatric and 
extrapulmonary TB) or inform the design of research studies in these patient groups. 
 
3.2 Materials and methods 
3.2.1 Study participants 
 
As described chapter 2 (section 2.1), we recruited individuals that were suspected of 
having pulmonary TB disease from primary health care clinics in Cape Town, South 
Africa,  prior to the diagnosis of TB or other respiratory diseases (ORD) in them.  This 
was a sub-study of a larger biomarker study that is currently ongoing in multiple African 
countries and known as the “ScreenTB” project (www.screen-tb.eu) and the inclusion 
and exclusion criteria were described in chapter 2 (section 2.1.1-2.1.2). 
 
3.2.2 QuantiFERON® TB Gold Plus ELISA 
 
As also described in chapter 2 (section 2.5) , whole blood was collected from all study 
participants by venepuncture, directly into tubes that were supplied by the 
manufacturers of the QFT Plus test (1 ml per tube, 4 tubes corresponding to the nil, 
TB1, TB2 and mitogen) as recommended by the manufacture (Qiagen, Germany).  
The tubes were then transported at ambient conditions to the laboratory after which 
they were incubated  overnight (18 to 24 hours) at 37 °C, in a 5% CO2 incubator, 
followed by centrifugation (3000 x g for 15 minutes) as recommended by the 
manufacturer. Culture supernatants were then harvested, aliquoted and frozen until 
used for ELISA. IFN-γ concentrations in the supernatants were then determined using 
QFT Plus ELISA kit and the results interpreted as positive, negative or indeterminate 
using the analysis software provided by the manufacture (Qiagen, Germany).  
 
3.2.3 Statistical analysis  
 
The sensitivity and specificity of the QFT Plus for TB disease was evaluated against 
the composite reference standard described in Chapter 2 (section 2.7). The 




concentrations of IFN-γ detected in the nil, TB1, TB2 and Mitogen stimulated 
supernatants were compared between patients with TB disease or ORD using the 
Mann Whitney U test.  Alternative cut-off values for discriminating between TB and 
ORD using any of these stimulation conditions were assessed using receiver operator 
characteristics curve analysis. The General discriminant analysis (GDA) procedure 
was used in evaluating combinations between the nil, TB1, TB2 and mitogen–specific 
IFN-γ values to ascertain whether the use of alternative cut-off values for each of these 
conditions could potentially provide an algorithm for the diagnosis of active TB. Finally, 
we evaluated whether the use of symptoms in combination with the test result obtained 
using the manufacture’s cut-off value had potential in the diagnosis of active TB 
disease. Prediction accuracy was evaluated using leave-one-out cross validation. As 
mentioned in chapter 2, all statistical analysis was performed using Graph Pad Prism 
version 7.04 and Statistica (Dell Software), with p-values ≤ 0.05 considered significant.     
This report especially the discussion section was written in the method proposed by 
Sacket and Haynes (124). 
 
3.3 Results  
3.3.1 Patient characteristics 
 
As previously described in chapter 2 a total of 104 study participants were 
prospectively recruited in to the study between (11/10/2016) and (19/10/2017). The 
mean age of all the study participants was 40 ± 12.6 years, with 14 (11%) being HIV 
infected. Using the manufacturer’s recommended cut-off value (0.3 IU/ml), 87 (72.5%) 
the study participants were QFT Plus positive. Using the reference standard described 
in chapter 2 (section 2.2), which made use of clinical information, laboratory (smear, 
GeneXpert and culture) and imaging results, 35 (33.6%) of the study participants were 
definite TB patients. In fact, all the TB patients were culture positive (table 3.1). The 
prevalence of different symptoms that led to the suspicion of TB disease, hence the 








Table 3.1:  Clinical and demographic characteristics of study participants. 
No of participants All TB disease ORD 
No. of patients 104 35 (33.6%) 69 (66.3%) 
Female’s n (%) 64 (53.3%) 10 (28.5%) 46 (66.6%) 
Age mean ± SD 40.06 ±1 2.58 34.8 ± 12.14 41.92 ± 12.6 
HIV positive n (%) 14 (13.4 %) 7 (20.0 %) 7 (10.1%) 
QFT plus Positive n (%) 87 (72.5%) 27 (77.1%) 49 (71%) 
QFT plus Negative n (%) 32 (26.7%) 8 (22.8) 20 (28.9) 
Indeterminate n (%) 1 (0.8) 0 (0) 0 (0) 
Symptoms at enrolment  
Coughing 115 (95.8%) 30 (85.7%) 69 (100%) 
Night sweats 99 (82.5%) 28 (80.0%) 56 (81.2%) 
Weight loss 79 (65.8%) 28 (35.4%) 38 (55.1%) 
Chest pain 91 (75.8%) 29 (31.8%) 51 (73.9%) 
Feverish 57 (21.1%) 25 (71.4%) 24 (34.8%) 
Weak and tired  75 (62.5%) 26 (74.3%) 41 (59.4%) 
Not feel like eating 73 (60.8%) 21 (60%) 42 (60.9%) 
35 of the study participants were definite TB and 69 were Non-TB (ORD). Participants 
were classified as Definite TB if they were smear positive, culture positive and had a 
chest X-ray suggestive of TB. Participants were classified as ORD if they were culture 
negative, smear negative and negative chest X-rays, and have never been under TB 
treatment initiated by health providers. QuantiFERON results was obtained and 
defined as positive, negative, and indeterminate by using manufacture’s software. 
Abbreviations: TB= Tuberculosis, ORD= other respiratory disease, SD=standard 
deviation, HIV= Human immunodeficiency virus, QFT= QuantiFERON TB Gold plus. 
 
3.3.2 Analysis of IFN-γ responses obtained in respective QFT Plus tubes 
 
We evaluated the magnitude of IFN-γ produced in the respective QFT Plus tubes from 
all study participants and also assessed differences between TB patients and those 
with ORD. The mean IFN-γ levels obtained in the nil tube was 0.34 ± 0.45 IU/ml. After 




subtraction of the nil values, the mean TB1, TB2 and mitogen-specific IFN-γ responses 
were1.93 ± 1.11 IU/ml, 2.36 ± 3.11IU/ml and 10.97 ± 2.90IU/ml respectively. When the 
mean IFN-γ levels were compared between TB and ORD, the mean IFN-γ levels in 
TB was higher than that of ORD. When IFN-ү levels were compared between TB and 
ORD groups, nil and mitogen-nil were the only tubes which showed significant 
difference between TB and ORD. the mean, standard deviation and p values from 
individual tubes are shown in table 3.2.  
 
Table 3.2: IFN-γ (IU/mL) concentration detected in unstimulated QFT Plus 
supernatants from individuals with TB disease (n=35) and other respiratory 
diseases (n=69). The concentrations were measured in each QFT Plus tube. 
Stimulant All 
(mean ± SD), (IU/ML) 
TB 
(mean ± SD), (IU/ML) 
ORD 
(mean ± SD), 
(IU/ML) 
P-value 
Nil 0.34 ± 0.45 0.34 ±0 .26 0.29 ± 0.27 0.0129 
TB1 2.21 ± 2.54 1.70 ± 1.84 2.35 ± 2.83 0.8017 
TB2 2.25 ± 2.81 2.458 ± 2.84 2.580 ± 2.84 0.6350 
Mitogen 1.86 ± 4.46 8.89 ±  4.46 10.20 ± 1.67 0.9808 
TB1-nil 1.93 ± 1.11 1. 36 ± 1.75 2.13 ± 2.81 0.5024 
TB2-nil 2.36 ± 3.11 2.45 ± 3.16 2.17 ±2 .82 0.8608 
Mitogen-nil 10.97 ± 2.90 9.98 ± 3.73 11.64 ± 1.76 0.0472 
 
3.3.3   Performance of QFT Plus in the diagnosis of TB disease 
 
As shown in table 3.1 (above), 72.5% of all study participants (patients with TB plus 
those with ORD) were positive with the QFT Plus test. Out of all the 35 TB patients, 
the test, using the cut-off values recommended by the manufacturer yielded positive 
results in 27, corresponding to a sensitivity of 77.1% (95% CI: 59.9-89.9%), specificity 
of 71.0% (95% CI: 58.98.3%), positive and negative predictive values of 57.5 (95% CI: 
47.32-67.1%) and 86.0 (95% CI: 76.59-92.0%) respectively. The area under the ROC 




curve for the QFT Plus test in the diagnosis of active TB in individuals in whom TB 
disease is suspected was 53.0% (95% CI: 44.3-61.8%). 
Given the relatively poor sensitivity and specificity of the test (that is, sensitivity falling 
below the expected threshold of 95% that is claimed by the manufacturer), we sought 
to determine whether there were alternative cut-off values derived using ROC curve 
analysis, which would yield better accuracy. When ROC curve analysis of IFN-γ values 
was done, values detected in the nil tube had the highest area under the ROC curve 
(AUC) as shown in table 3.3. The cut-off values, sensitivity, specificity, positive and 
negative predictive values as well as area under the ROC curves are shown in table 
3.3. 
 
Table 3.3: Diagnostic accuracies for IFN-ү detected in different QFT Plus tubes 
from individuals with TB disease (n=35) and other respiratory diseases (n=69). 
Stimulant Cut-off AUC (95%CI) Sensitivity  Specificity  P value 


















































AUC= Area under the ROC curve, CI= Confidence interval. p<0.005 is considered 
significant 




After performing GDA analysis to evaluate combinations between the QFT Plus tubes, 
the sensitivity of the QFT Plus test with the GDA derived cut-off value (0.44) was 
inferior to that obtained using the manufacturer’s recommended cut-off value, even 
though there was an improvement in the specificity. The sensitivity of the GDA 
combinations of antigen-specific IFN-γ values was 42.9% (95% CI: 23.3-60.7%) and 
the specificity was 88.4% (95% CI: 78.43-94.9%). After leave–one-out cross 
validation, the sensitivity and specificity were 44.9% (95% CI: 26.3-60.7%) and 87.0% 
(95% CI: 16.7-93.9%) respectively. The positive and negative predictive values were 




Figure 3.1: ROC curve for diagnosis of TB disease using combination of IFN-γ 
values detected in QFT Plus antigen tubes (nil, TB1-nil, TB2-nil and Mitogen-nil) 
using alternative cut-off values (A). The scatterplot (B) represents the classification of 
each study participant by the GDA derived model. 
 
3.3.4 Performance of QFT-Plus test in the diagnosis of TB disease when used 
in combination with symptoms.   
 
We investigated whether the use of symptoms in combination with the QFT Plus test 
result obtained using the mufacturere’s cut-off value had any potential in the diagnosis 
of active TB. A combination of three symptoms diagnosed TB disease with sensitivity 
and specific of 77.0% (95%CI: 56.4-91.0 %) and 70.0% (95% CI: 56.0-81.2 %) 






































respectively, with an AUC of 0.81 (95%CI: 0.71-.91%). After leave-one-out cross 
validation, there was no change in the sensitivity and specificity (Table 3.4 A). When 
the QFT Plus was used in combination with symptoms, there was an added benefit of 
combing both results as a combination of QFT Plus results and four symptoms 
including not feel like eating, weight loss, feverish and sharp chest pains which 
resulted in an increased sensitivity of 80.0% 95% (CI: 91.4-92.3% ) and specificity of 
77.0% (95%CI: 54.9-81.3%) and after leave-one-out cross validation, the sensitivity 
and specificity were 76.7% (95%CI: 57.2-90.1%) and 69% (95%CI: 54.9-81.3%) 
respectively (Table 3.4 B). 
  
Table 3.4: Diagnostic biosignatures identified in the current study. The GDA 
modelling procedure was performed in all TB study participants 
 Classification 
matrix 













Biosignature (i): symptoms only 










    52.6  
(41.80-
63.2) 
    86.7 
(75.1-93) 
Biosignature (ii): symptoms and QFT Plus positive results 
Not feel like eating + 
weight loss + feverish + 
sharp chest pains + 



















   
Figure 3.2: ROC curve for diagnosis of TB disease using combination of 
symptoms only and symptoms plus QFT Plus positive results. A, represents 
combination of symptoms only and B, represents combination of symptoms and QFT 




We evaluated the accuracy of QFT Plus test in the diagnosis of active TB amongst 
patients with suspected TB disease. Additionally, we investigated whether this test 
had potential in diagnosing TB when alternative cut-off values were used and also 
when used in conjunction with TB symptoms. Our main findings was the ability of the 
QFT Plus test, using the manufacturer’s recommended cut-off value to diagnose active 
TB with sensitivity and specificity of 77.1% and 71.0% respectively as shown in table 
3.1. When used alone, a combination of three symptoms coughing, being feverish plus 
weight loss diagnosed TB disease with sensitivity and specificity of 77.2% and 70.4% 
respectively, and an AUC of 0.81.We hypothesized that the use of the two modalities 
(symptoms and QFT Plus results) in combination would lead to an incremental 
sensitivity and specificity, compared to the values obtained with these tests (symptoms 
and QFT Plus result) alone. When the QFT Plus positive results were used in 
combination with symptoms, the addition of QFT Plus did not have any additional value 
over the symptoms alone. On the contrary, QFT Plus positive results + symptoms 
resulted in inferior accuracy to the QFT Plus alone or combination of symptoms alone. 
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Study strength and weaknesses of the study 
There are several studies in the literature in which the QFT (especially previous 
versions as the current is still relatively new) were assessed for their potential in the 
diagnosis of TB disease (125-126) in both high and low TB burden settings. It is known 
that the QFT tests are primarily designed for the diagnosis of infection with M. tb. 
However, as there is no gold standard test for the diagnosis of M. tb infection, data 
obtained from TB studies provide evidence of the true sensitivity of the test, since 
people with newly diagnosed, untreated active TB (such as those employed in the 
current study) are definitely infected. A limitation to this approach though is the fact 
that TB patients may have anergic T cells, thereby compromising on the sensitivity 
evaluation, however, as there is no gold standard for M. tb infection, TB patients 
represent the best group in which the sensitivity of tests for M. tb infection can be 
assessed. 
 According to a systemic review and meta-analysis by Sester et al (123), reported that 
the pooled sensitivity of IGRAs do not show any supplemental value in diagnosing 
active TB even when combined with TB diagnostic standard methods (123). However, 
none of these studies were conducted in individuals with symptoms suggestive of TB 
disease. As QFT Pus is a newly introduced in vitro test which has been reported to 
offer improved sensitivity, mostly because of the additional TB2 antigen tube, this 
study had an opportunity to evaluate its performance in a TB endemic region in people 
with TB symptoms. Furthermore, given the reportedly high sensitivity and specificity 
of this test, according to the  manufacturer, the current study was able to able to assess 
the ability of this test to be used in combination with TB symptoms as this might be 
helpful in diagnosing TB, with higher predictive values. 
While the sample size of this study was reasonable, especially as it was a study in 
which study participants were recruited prospectively, it might have been better if we 
had more study participants so as to increase the proportion of people for example, 
who are HIV co-infected. The small number of HIV infected individuals led to the 
inability of this study to assess the effect of HIV infection on the QFT Plus test since 
evidence from previous studies showed that the previous generation of the test was 
affected by HIV infection but current evidence suggests that the QFT Plus test is not 
affected by HIV infection although the viral and CD4 count was not assessed, in fact 




it has been shown to work better in HIV and other immunocompromised individuals 
(128). This limitation is however not major as the strengths of the current study 
outweigh the limitations. That is, participants were recruited prospectively, therefore 
the proportion of HIV individuals is concurrent with what one would normally expect at 
a community health care centre, such as where the study participants were recruited. 
Power calculations done for the main ScreenTB project showed that the number of 
study participants enrolled into the project were sufficient. However, more independent 
studies in which the manufacturer of the kits is not involved are required to confirm the 
findings for this study in participants from both high and low TB endemic countries. 
The relation of the current study with other studies 
The data for the performance of QFT Plus test in the diagnosis of TB of either M. tb or 
active TB disease is currently limited. However, studies which were conducted in 
previous QFT (QFT-TB Gold In tube) tests have demonstrated that this test may be 
useful in diagnosing TB disease in high TB settings (129), with a pooled sensitivity and 
specificity of 80% and 79% in case control study performed in all patients with TB (non-
confirmed and confirmed by culture)  (123). The manufacturer of the QFT Pus test has 
reported that this test offers increased sensitivity as high as 87% against culture 
confirmed TB (122) with sustained high uninterrupted specificity more especially to 
immunocompromised individuals as well as individuals living with HIV infection. QFT 
Plus results from culture confirmed TB varies. A study by Barcellini et al (74) reported 
a sensitivity of 87.9% (85), Hoffman et al, (132)    95.8% in culture confirmed TB. Our 
study found a sensitivity of 77.1% which is similar to the findings from these studies. 
The low specificity (71.0%) reported in the present study maybe because unlike other 
studies which included selected study participants in case-control or cross-sectional 
studies, our study included participants who were suspected of having active TB 
disease, prior to the confirmation or rule-out of TB disease, which is a stronger (phase 
III) design for a diagnostic study (131). 
Implications of the current study  
Although some studies reported against the use of QFT test in diagnosing TB in TB 
endemic regions. A positive QFT Plus test together with a combination of symptoms 
may still be useful in the diagnosis of TB in certain patient groups and such a 
diagnostic modality may act as a screening tools for active TB, for later confirmation 




with gold standard TB diagnostic tests. This may be of particular relevance to 
extrapulmonary TB or childhood TB diagnosis, where current diagnostic approaches 
have limited applicability.  
In the current study, the levels of IFN-ү obtained in individual antigen tubes did not 
show any significant difference between the ORD and TB group although the median 
TB2 IFN- γ levels were higher than in TB1 antigen tube (Table 3.2). This might have 
resulted due to our small sample size. HIV-confected active TB patients may have 
also affected the concentration levels of IFN-ү although no conclusions can be made 
about the effect of HIV infection, hence the CD4 count and vial load was not assed. 
However, the similar results were obtained in a study conducted by YI et al (72). They 
reported that no significant difference was found between the two antigen tubes. The 
difference shown in these TB antigen tubes may suggests that QFT Plus was sensitive 
in diagnosing active TB disease which may have been influenced by the additional 
TB2 antigen tube (72). Recent studies suggests that the TB2 antigen tube is highly 
sensitive in people with active TB, children, HIV infected patients and recent exposure 
which may therefore supports our findings. Additionally, the current study evaluated 
the relative cut-off values for accuracy of QFT Plus and individual tubes.  The best cut-
offs selected for individual tubes in this study showed promising optimal sensitivity and 
specificity, however no conclusion can be made from these findings until more studies 
are done. Furthermore, our statistically derived cut-off value of 0.4 UI/mL did not show 
any significant difference at all when compared to the manufacturer cut-off (0.35 
UI/mL).  
Unanswered questions and future research 
Considering the relatively small number of HIV infected individuals enrolled in the 
current study, future studies for evaluating the performance of this test in individuals 
with TB symptoms and HIV infection may be beneficial and will add to the few studies 
that have been reported in the literature about the QFT Plus test. As this study was 
conducted in a high TB endemic region, similar studies conducted in low TB settings 
may be beneficial in order for conclusions about the performance of the test in the 
diagnosis of active TB to be made. Additionally, as diagnosing TB in children is 
problematic, it may be important that future studies should look at the performance of 
this test in children with and without HIV infection in both high and low TB settings. 




HIV infected individuals included in these further studies should be appropriately 
staged with CD4 counts and viral loads to determine the effect of extensive HIV 
infection on the test results. Furthermore, confirmed other respiratory diseases will 
help in identifying specific groups e.g. patients with pneumonia, which may influence 
the specificity of the TST. 
Conclusion 
To conclude, this study was one of the first to evaluate the accuracy of the QFT Plus 
in people in whom TB is suspected, independently and in a high burden setting. 
Although 71.0% of individuals without active TB and who presented with other 
respiratory diseases yielded positive results with the test, thereby indicating the high 
LTBI in the population, the sensitivity and specificity of the test was still 77.1% and 
71.0% respectively. When combination of symptoms was used to diagnose TB and 
was 80.0% and 77.0% respectively when positive QFT Plus results were used in 
combination with symptoms. The test may therefore have a role in the diagnosis of 
active TB, especially in difficult to diagnose TB groups such as HIV infected 
individuals, children and those with extrapulmonary TB. However, as that was not the 
focus of the current study, such investigations were not done. Therefore further studies 
evaluating the accuracy of the QFT Plus are needed before any conclusions can be 
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An estimated 2 billion people were reported to be infected with Mycobacterium 
tuberculosis (M. tb), the causative agent of tuberculosis (TB), with about 10 million 
reported to have fallen ill with active TB in 2017 (6).  About 1.3 million people were 
reported to have died of the disease in the same year (6). The widely publicised 
limitations of the currently existing diagnostic procedures (132, 133) is one of the 
reasons why TB continues to be a problem.  The most widely used TB diagnostic test 
(smear microscopy) (86) has poor sensitivity, whereas culture; the gold standard has 
long turnaround time, is prone to contamination, expensive and it is not available in 
many resource poor settings (111). The Gene Xpert MTB/RIF test (Cepheid, 
Sunnyvale, CA, USA ), the most important recent development in the TB diagnostic 
field yields results within 2 hours, and detects resistance to rifampicin, one of the first-
line TB drugs, but is expensive and cannot distinguish between DNA from dead and 
live bacteria (6). These tests rely on the availability of a good quality sputum specimen, 
which is problematic for the diagnosis of TB in children and individuals with other 
paucibacillary forms of the disease such as those with extrapulmonary TB (133). 
Immunological diagnostic approaches have been shown to be potentially useful and 
may be easily converted into point-of-care screening tests (95, 98, and 100). 
 
Despite ongoing research into the development of immunological diagnostic tests, the 
tuberculin skin test (TST) and interferon gamma (IFN-γ) release assays (IGRAs) 
remain the only approved immunodiagnostic tests for the management of TB. These 
tests are useful in identifying people who are infected with M.tb but do distinguish 
active TB from latent infection (LTBI) [100, 102,136). They are therefore not 
recommended for use in high burden settings, due to the high prevalence of LTBI (6). 
Given the probable easier application of blood-based tests in the diagnosis of TB, 
multiple investigators have evaluated other antigens other than those used in IGRAs 
(ESAT-6, CFP10 and TB 7.7) or alternative host biomarkers other than IFN-γ; the 
read-out biomarker in IGRAs (100, 102) as active TB diagnostic tools. Most of these 
investigations, which were done in QuantiFERON® TB Gold (QFT) In Tube culture 
supernatants (100, 103) identified promising biosignatures for the diagnosis of active 
pulmonary TB disease in both adults (100, 102, 134) and children (118. 135). The QFT 




In Tube has since been replaced by the QFT Plus. This new version of the test (QFT 
Plus), unlike the QFT In Tube which had three tubes namely; nil control, TB antigen 
and mitogen, contains a second TB antigen tube. Furthermore, the TB antigen tube in 
the QFT In Tube system contained ESAT-6, CFP10 and TB 7.7 peptides, but the QFT 
Plus only contains CFP-10 and ESAT-6 peptides (123) with the TB antigen (TB1) tube 
containing long peptides that elicit CD4 cell immune responses and the TB2 tube 
containing short and long peptides which elicit CD4 and CD8 T cell immune response 
(139).  
Given that host immunological biomarkers detected in QFT In Tube supernatants were 
shown to have potential as diagnostic biomarkers for TB disease in several studies, 
reviewed in (136), it is not certain whether the findings from these studies can be 
replicated in supernatants from the QFT Plus system. Furthermore, as the QFT Plus 
is reportedly more accurate in the diagnosis of M. tb infection than the QFT In Tube, 
owing to the inclusion of the second antigen tube (122, 130), it is not known whether 
the use of alternative biomarkers detectable in QFT Plus supernatants will perform 
better in the diagnosis of TB disease than what was obtained with the QFT In Tube 
system.  
The aim of the present study was therefore to evaluate the utility of host immunological 
biomarkers that have previously been shown to possess potential as biomarkers for 
active TB or discrimination between LTBI and active TB using the QFT In Tube system, 
in QFT Plus supernatants, in individuals suspected of having TB disease, recruited 
from a high TB endemic setting. We therefore evaluated the utility of biomarkers that 
have previously been shown to possess potential in the diagnosis of M. tb infection or 
disease in previous studies including studies done in serum, plasma and QFT In Tube 
supernatant samples (section 4A) and 19 relatively newer host biomarkers, mainly 
complement proteins in a subset of study participants (section 4B). The relatively 
newer host biomarkers (reported in section 4B) were only evaluated in a limited 
number of study participants because our aim was to generate preliminary data on the 
potential utility of these biomarkers, with the aim of evaluating promising candidates 
in future larger studies. The reasons for not evaluating these host biomarkers in all 
study participants were primarily cost related, as Luminex immunoassay kits 
containing these relatively newer markers are expensive.  





4.2 Materials and Methods 
 
As described in chapter 2.1 (figure 2.2), QFT Plus supernatant from a total of 120 
study participants were evaluated. Sample collection and processing, diagnostic tests 
including QFT Plus ELISA and the reference standard were described in chapter 2 
(sections 2.4 and 2.5 and 2.7.2 respectively). 
 
4.2.1 Luminex multiplex immunoassay  
 
As described in chapter 2, section 4.2.5, we evaluated the concentrations of 37 host 
biomarkers which showed potential as TB diagnostic candidates in previous studies 
(103, 113, 114) in the nil, TB1 and TB2 stimulated supernatants from all study 
participants. These host markers included apolipoprotein (Apo) A-1, Apo-CIII, 
complement factor H (CFH), IFN-α-2, macrophage inflammatory protein 1-alpha 
(CCL4/MIP-1 α ), interleukin 4 (IL-4), IL-6 which were purchased form Merck Millipore 
(Merck Millipore, Billerica, MA, USA), and neural cell adhesion molecule-1 (NCAM-
1/CD56), transforming growth factor (TGF)-α, IFN-γ, monokine induced by IFN-γ 
(CXCL9/MIG), p-selectin, epidermal growth factor (EGF),  tumour necrosis factor 
superfamily member 14 (TNFSF14/LIGHT), monocyte chemotactic protein (MCP)-1 
(CCL2), MCP-2 (CCL8), macrophage inflammatory protein-1 beta (MIP)-1β, vascular 
endothelial growth factor  (VEGF), a disintegrin and metalloproteinase with a 
thrombospondin type 1 motif, member 13 (ADAMTS13), CD40 ligand (CD40L) , 
interferon inducible T-cell alpha chemoattractant (CXCL11/ITAC-1), IFN-γ inducible 
protein (IP) -10 (CXCL10),  tumour necrosis factor (TNF)-α,  Fas , interleukin (IL)-1β, 
granulocyte monocyte colony stimulating factor (GM-CSF), IL-8 (CXCL8), IL-3, IL-15,  
IL-13, IL-2, IL-33, IL-1α, IL-10, interleukin- 1 receptor agonist (IL)-1ra, and IL-22 which 
were purchased from R&D Systems Inc. (Biotechne, Minneapolis, MN, USA). All 
experiments were run on the Bio-Plex 200 or Magpix platform (Bio-Rad Laboratories, 
Hercules, USA) with the Bio-Plex Manager Software (version 6.1) used for bead 
acquisition and analysis of median fluorescent intensity (Bio-Plex 200) or Bio-Plex MP, 




followed by Bio-Plex manager 6.1 (for assays run on the Magpix). The values of the 
proteins in the respective quality control reagents were within the expected ranges. 
 
4.2.2 Statistical analysis  
 
As described in chapter 2 (section 2.9), Graph Pad Prism version 7.04 (San Diego, 
CA, USA) and Statistica (TIBCO Software Inc., CA, USA) were used for all statistical 
analysis done in this chapter. The differences in the concentrations of individual host 
biomarkers between TB vs. ORD groups were assessed using Mann-Whitney U-test. 
The diagnostic accuracy of individual biomarkers were evaluated by receiver operator 
characteristics (ROC) curve analysis. Youden’s Index was used to determine the Cut-
off values and associated sensitivity and specificity. The predictive abilities of 
combinations between multiple host biomarkers was assed using general discriminant 
analysis (GDA), with prediction accuracy ascertained by leave-one-out cross 
validation. p≤ 0.05 were considered significant. 
 
4.3 Results 
Section 4 A: Evaluation of the potential of previously identified host 
biomarkers as tools for the diagnosis of M. tb disease or infection, in QFT Plus 
supernatants 
 
In this section, we evaluated the utility of the 37 host biomarkers which previously 
showed potential in serum, plasma or QFT In Tube supernatants as potential 
biomarkers, in the QFT Plus supernatants. Our primary aim was to determine whether 
biomarkers that previously showed potential in QFT In Tube supernatants would 
perform better in QFT Plus supernatants, given that the kit manufacturer claims that 
the QFT Plus has superior performance, compared to the QFT In Tube assay. We 
therefore also included the recently identified biomarkers (from serum and plasma 
based studies), to ascertain the potential of antigen-specific levels of these biomarkers 
in the diagnosis of TB disease or M. tb infection. 
    




4.3.1 Patient characteristics 
 
A total of 104 participants; mean age, 40 ± 12.6 years, 56 (46.7%) of whom were males 
were included the study (Figure 2.1) with 14 (13.5%) of the participants being HIV 
infected. Using the manufacturer’s recommended cut-off value (≥0.3 IU/ml), 87 
(72.5%) of the study participants were QFT Plus positive. We planned to use a pre-
established composite reference standard that includes clinical information, laboratory 
(smear, GeneXpert and culture) and imaging results to classify study participants as 
definite TB, probable TB or ORD as done in previous studies (101,114) but 
surprisingly, all the 35 (29.1%) individuals that were finally diagnosed with TB  were 
culture positive (Table 4.1).  
 
Table 4.1. Clinical and demographic characteristics of study participants. All 
study participants were culture positive. 
  TB disease ORD 
No. of patients 104 35 (29.1%) 69 (70.8%) 
Female’s n (%) 64 (53.3) 10 (28.5) 46 (66.6%) 
Age mean ± SD 40.06 ± 12.58 34.8 ± 12.14 41.92 ± 12.6 
HIV positive n (%) 14 (13.5%) 7 (20.0 %) 7 (10.1%) 
QFT plus Positive n (%) 87 (72.5%) 27 (77.1) 49 (71%) 
QFT plus Negative n 
(%) 
32 (26.7%) 8 (22.8) 20 (28.9) 
Indeterminate n (%) 1 (0.8) 0 (0) 0 (0) 
QuantiFERON results were obtained and defined as positive, negative, and 
indeterminate by using the manufacture’s software. Abbreviations:  TB= Tuberculosis, 
ORD= other respiratory disease, SD= Standard deviation, HIV= Human 
immunodeficiency virus, QFT= QuantiFERON TB® Gold plus. 
 
4.3.2 Utility of individual host markers in the diagnosis of TB 
 
We assessed the usefulness of all 37 host markers that showed potential in previous 
studies (99-107) in QFT Plus supernatants using the Mann Whitney U test. The 




concentrations of the host markers detected in the nil (unstimulated) supernatants and 
the TB1 and TB2 antigen-specific values (TB1 minus nil and TB2 minus nil) 
respectively,  were evaluated separately so as to assess the potential usefulness of 
markers detected in the nil supernatants as done in previous studies (100, 113).   
 
4.3.3 Host markers detected in unstimulated (nil) supernatants 
 
When the values obtained in nil supernatants from TB patients were compared to 
responses obtained in the individuals with other respiratory diseases (ORD), 
regardless of HIV infection status, significant differences (P≤0.05) were obtained in 
the concentrations of 14 of the 37 markers. The median concentrations of ITAC-1, IL-
3, I-309, MIG, Apo-A1, ADAMTS13, GM-CSF, IL-22, and TGF-α were significantly 
higher in the TB patients whereas, the concentrations of IL-1α, IL-33, Apo-A1, and IL-
2 were significantly higher in the ORD group (Table 4.2).  When the diagnostic 
accuracy of the markers detected in the nil supernatants were assessed using ROC 
curve analysis,  the areas under the ROC curves (AUCs) were  all ≥0.65 for the same 
14 analytes, with ITAC-1, IL-3, I-309, and MIG being the most accurate individual 
markers as determined by AUCs > 0.70 (Figure 4.1). When only the HIV uninfected 
individuals were considered, only the same 14 host markers showed significant 












Table 4.2: Median (Inter-quartile ranges in parenthesis) levels and diagnostic 
accuracies of host biomarkers detected in unstimulated QFT Plus 
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ITAC-1        310  
(238-450) 
       561 
 (381-753) 







IL-3         35  
 (24-43) 
        44 
(38-48) 
0,0008         0.75 
(0.63-0.86) 
>40.85 76  
(53-92) 
65 (52-76) 
I-309        11            
(8-13) 
    18  
 (10-26) 
0,0001         0.73 
(0.62-0.84) 
>11.09 71  
(54-85) 
55(43-67) 
MIG        890 
(772-1095) 
      1133  
 (873-
1645) 







Apo CIII  281738 
(169471-
838212) 
   122386 
(80337-
295193) 




71 (54-85) 65 (53-76) 
IL-1α          43     
    (23-67) 
      62  
(47-78) 
0,0066        0.69 
 (0.57-0.81) 
>50.87 74 (52-90) 62 (49-73) 
IL-33         20  
     (3-45) 
     41  
  (29-55) 
0,0065       0.69 
 (0.58-0.81) 
>28.20 78 (59-92)  58 (45-71) 
Apo-A1   710225 
 (394468-
1525800 
   346446 
 (190034-
653295 




73 (54-87) 65 (53-76) 
ADAMTS
13 




     71289 
(71289-
1496500) 




67 (47-86) 64 (57-80) 
IL-2      1180 
 (563-1552) 
  1555 0,0145      0.67 
 (0.55-0.76) 
>1363 70 (47-87) 65 (50-75) 










  100864 
 (75770-
132990) 




72 (53-86) 54 (41-66) 
GM-CSF        37 
  (23-56) 
    62  
(25-94) 
0,0134        0.65 
 (0.53-0.77) 
>40.81 71 (54-85) 55 (43-65) 
IL-22       28      
   (15-41) 
     36  
(31-44) 
0,0389        0.65 
 (0.53-0.77) 
>29.12 90 (69-99) 57 (44-96) 
TGF- α                                                                   23 
  (18-34) 
31 (19-51) 0,0213        0.64 
 (0.53-0.76) 
>28.32 64 (45-80) 65 (53-76) 
Only biomarkers which showed significant differences or trends in the Mann Witney U 
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Figure 4.1: Concentrations of host biomarkers detected in unstimulated (Nil) 
QFT plus supernatants from individuals with TB disease and individuals with 
other respiratory diseases (graphs A-O). Receiver operator characteristic curves 
showing the accuracies of with these host biomarkers are shown (graphs AA-OO), 
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where AA is the ROC curve for the marker shown in figure A, BB, that for the marker 
in figure B. 
 
4.3.4 Host markers detected in TB1 antigen stimulated supernatants  
 
When the TB1 antigen-specific levels of the host markers were compared between the 
TB and ORD groups, median levels of MIP-1α, LIGHT, and IL-13 were significantly 
higher in the TB patients whereas those of P-selectin, IL-2, IL-10 and GM-CSF were 
higher in ORD group (Table 4.3). When ROC curve analysis was done, seven of the 
37 markers discriminated between the two groups with AUC ≥0.60, with MIP-1α, p-
selectin, and IL-2 being the most accurate TB1-speficic host markers (Figure 4.2).  
 
Table 4.3: Median levels (inter-quartile ranges in parenthesis) of QFT Plus TB1-
antigen-specific host markers as detected in individuals with TB or other 




















    0.197 
(-0.3806-
0.6405) 
     -0.4173  
(-1.447-
0.4049) 
0.0277      0.66 
(0.52-0.80) 
0.04329      68 
(45-86) 
      60 
(47-72) 
MIP-1α       -0.1339 
(-0.2646-
0.3281) 
       0.2562  
(-0.537-
0.04445) 
0.0816    0.6445 
(0.53-0.76) 
-0.1554      70 
(51-84) 
   55 
(43-67) 
IL-2     -0.137 
(-0.2132-
0.7377) 
   -0.088795 
(-0.0341-(-
0.1149) 
0.0491     0.6409 
 (0.52-
0.74) 
0.4564     68 
(45-86) 
   60 
(44-69) 
LIGHT       -0.0934 
(-0.7485-
0.7281) 
   -0.4049 
(-0.792-
0.1191) 
0.0794       0.63 
(0.50-0.73) 
-0.2076       71 
(48-89) 
     52 
(40-65) 




IL-13     -0.0892 
(0.2827.518
) 
  -0.2463 
(-0.518-
0.0051) 
0.0484     0.6212 
(0.51-0.57) 
-0.128      70 
(0.51-0.84) 
     54 
(41-66) 
GM-CSF    0.2213 
(-0,3758-
0.2015) 









     66 
(48-81) 
     62 
(50-74) 
IL-10    0.2727  
(-0.2287-
0.7325) 
     0.00814  
(-0.4544-
0.2281) 
0.0548     0.6179 
(0.51-0.73)  
0.2201      73 
(55-88) 
    52 
(40-64) 
Only biomarkers which showed significant differences or trends between the two 
groups using the Mann Witney U test are shown. Cut-off values were selected based 
on the Youden’s index. The negative values shown indicate that the concentrations of 
the host biomarkers detected in the QFT Plus TB1 tube were lower than values 
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Figure 4.2: Concentrations of host biomarkers detected in QFT Plus TB1 
supernatants. Representative plots for the antigen-specific levels of the host markers 
(TB1-nil) that showed significant differences with the Mann Whitney U test (p≤0.05) 
are shown in graphs A to G and receiver operator characteristic curves showing 
accuracies of these markers in diagnosing TB disease are shown in figures AA-GG). 
The negative values in figures A to G indicate that the unstimulated levels of the 
specific analyte were higher than the values obtained in the TB1 antigen-stimulated 
samples. 
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4.3.5 Host markers detected in TB2 antigen stimulated supernatants  
 
When the TB2-antigen-specific concentrations of the host markers were compared 
between patients with TB Vs. ORD, the median levels of IL-13, TGF-α, and MIP-1α 
were higher in the TB group whereas p-selectin, EGF, IL-10, and GM-CSF levels were 
higher in the ORD group (Table 4.4). EGF and p-selectin were the most accurate 
individual TB2-antigen-specific markers with AUCs of 0.66 (95%CI, 0.54-0.81) and 
0.65 (95% CI, 0.52-0.78) respectively (Figure 4.3). 
 
Table 4.4. Median levels (interquartile ranges in parenthesis) and diagnostic 
accuracies for host biomarkers detected in TB2 stimulated QFT Plus sups 















  0.1928 
(-0.402-
0.7307) 
  -0.2961 
(-1.35-
0.2293) 
0,0161      0.66 
(0,54-0.81) 
0.0309     76 
(53-92) 
     60 
(47-72) 
EGF    0,6551 
(-0.4189-
0.5737) 
   0.2845 
(0.7855-
0.0088) 
0.0333      0.65 
(0.52-0.78) 
-0.0172     77 
(55-92) 
    62 
(49-73) 
GM-CSF     0.1559 
(-0.3593-
0.6323) 
   -0.1459 
(-0.6546-
0.1884) 
0.0327     0.63 
(0.51-0.75) 
-0.1396      66 
(48-81) 
     65 
(53-75) 
IL-10      0.1892 
(-0.5080-
0.6323) 




0.0384      0.63 
(0.51-0.74) 
0.0988     73 
(54-88) 
    61 
(48-72) 
TGF-α       0.086 
(0,8910-
0.3405) 
  0.152 
(-0.5266-
0.9270) 
0,02068    0.56 
(0.45-0.70) 
-0.0823       60 
(38-63) 
     51 
(38-63) 




Values shown are TB2 antigen-specific levels, obtained by subtraction of the nil from 
the TB2 antigen stimulated values. Only biomarkers which showed significant 
differences between the two groups with p<0.05 in the Mann Witney U test are shown. 


















 P -S e le c tin  T B 2 -N il









A U C = 0 .6 6 (0 .5 4 -0 .7 0 )
A
AA












E G F  T B 2 -N il









A U C = 0 .6 5 (0 .5 2 -0 .7 8 )
B
BB












 G M -C S F  T B 2 -N il









A U C = 0 .6 3 (0 .5 1 -0 .7 5 )
C
CC







Figure 4.3: Concentrations of host biomarkers detected in TB2 stimulated QFT Plus 
supernatants from individuals with TB disease and individuals with other respiratory 
diseases (graphs A-G) and receiver operator characteristic curves showing accuracies 
of these markers in diagnosing TB disease. Representative plots for markers with AUC 
>0.50 are shown (graphs AA-GG). 
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4.3.5 Utility of combinations between different biomarkers in the diagnosis of 
TB 
 
We evaluated the utility of combinations between host biomarkers detected in culture 
supernatants from the different stimulation conditions alone by general discriminant 
analysis (GDA), followed by evaluation of biosignatures comprising of combinations 
between biomarkers derived from the antigen stimulation conditions (TB1-nil and TB2-
nil together). 
When we evaluated the usefulness of combinations between biomarkers detected in 
unstimulated supernatants, regardless of HIV infection status of study participants,  
a six-maker biosignature comprising of Apo-A1, ITAC-1, I-309, MIG, MCP-2 and 
NCAM diagnosed TB with an AUC of 0.91 (0.88-0.97) , corresponding to a sensitivity 
and specificity of 73.9% (95% CI, 51.6-89.8%) and 87.61% (95% CI, 77.2-94.5%) 
respectively (Table 4.5). After leave-one-out cross-validation, the sensitivity of the 
biosignature was 73.91% (95% CI, 51.6-89.8%) and specificity was 86.2% (95% CI, 
75.3-93.5%). The positive and negative predictive values (PPV and NPV) of the 
biosignature after leave-one-out cross validation were 68.0% (95% CI, 51.5-81.0%) 
and 90.5% (95% CI, 82.6-91.0%) respectively. When only the HIV uninfected 
participants were considered, a four-marker (unstimulated) biosignature comprising of 
Apo-CIII, I-309, MIG and NCAM similarly diagnosed TB disease with an AUC of 0.91 
(0.85-0.98) , corresponding to a sensitivity of 82.4% (95% CI, 56.6-96.2%) and 
specificity of 87.3% (95% CI, 76.5-94.4%) and with sensitivity and specificity of 76.5% 
(95% CI, 50.1-93.2%) and 85.7% (95% CI, 74.6-93.3%) respectively after leave-one-
out cross validation. The PPV and NPV after leave-one-out cross validation were 
59.1% (95% CI, 42.8-73.4%) and 93.1% (95% CI, 85.0-96.8%) respectively.  
 
When the TB1 antigen-specific marker values were similarly fitted into GDA models, 
regardless of HIV infection status, a four-marker signature comprising of Apo-CIII, I-
309, MIP-1α and TNF-α diagnosed TB disease with an AUC of 0.72 (95% CI, 0.61-
0.88), with sensitivity and specificity of 62.9% (95% CI, 44.9-78.2%) and 73.3% (95% 
CI, 66.7-87.3%) respectively . After leave-one-out cross validation, the sensitivity and 
specificity of the biosignature were 54.3% (95% CI, 36.7-71.2%) and 72.5% (95% CI, 




60.4-82.5%) respectively (Figure 4.4). The predictive values after leave-one-out cross 
validation are shown in table 4.5.  
 
When TB-2 antigen-specific markers were fitted into GDA models, again regardless 
of HIV infection status of participants, a four-maker biosignature comprising of IL-6, 
MIP-1a, GM-CSF, TGF-α  diagnosed TB disease with an AUC of 0.72 (95% CI, 0.60-
0.84), corresponding to a sensitivity 60.0% (95% CI, 42.0-76.1%) and specificity of 
79.1% (95% CI, 68.3-88.4%) (Table 4.5). After leave-one-out cross validation, the 
sensitivity of the biosignature was 57.1% (95% CI, 65.1-86.1%) and the specificity was 
71.6% (95% CI, 39.4-73.7%). The PPV and NPV of the signature after cross validation 
were 60.0% (95% CI, 46.9-72.0%) and 79.7% (95% CI, 63.5-81.3%) respectively 
(Figure 4.4).  
 
When we evaluated combinations between TB1 and TB2 antigen-specific 
markers, again, regardless of HIV infection status, a four-marker biosignature 
comprising of TNF-α, LIGHT, MIG, and p-selectin diagnosed TB disease with 
sensitivity and specificity of 77.3% (95% CI, 54.6-92.2%) and 72.3% (95% CI, 59.8-
82.7%) respectively (Table 4.5). After leave-one-out cross validation, the sensitivity 
and specificity of the biosignature were 77.3% (95% CI, 54.5-92.2%) and 69.2% (95% 
CI, 56.6-80.1%) respectively (Figure 4.4). 
Table 4.5: Summary of biosignatures (] in unstimulated, TB1, TB2 and TB1&TB2 
stimulated supernatants) identified in the current study. AUC = Area under the 
ROC curve, Spec= Specificity, Sens= Sensitivity, PPV= Positive predictive values, 
NPV= Negative predictive value. 










































































































Biosignature (v): Combinations between TB1 and TB2 antigen-specific biomarkers, regardless of 
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Figure 4.4. Usefulness of combinations of host markers detected in QFT Plus 
supernatants in diagnosis of TB disease. ROC curves and scatter plots showing 
the accuracies of the different biosignatures described in the text and table 4.5. The 
red squares in the scatter plots represent TB group and the blue squares represent 
ORD group from the scatter plots. A, ROC curve showing the accuracy of biosignature 
(i): combinations between unstimulated host markers regardless of HIV infection, and 
AA, scatter plot showing the distribution of TB patients and those with ORD as 
classified by biosignature (i). B, ROC curve showing the accuracy of biosignature (ii): 
combinations between unstimulated markers in HIV uninfected individuals and BB, 
scatter plot showing the distribution of TB patients and those with ORD as classified 
by biosignature (ii). C, ROC curve showing the accuracy of biosignature (iii): 
combinations between TB1 antigen-specific host markers regardless of HIV infection, 
and CC, scatter plot showing the distribution of TB patients and those with ORD as 
classified by biosignature (iii). D, ROC curve showing the accuracy of biosignature (iv): 
combinations between TB2 antigen-specific host markers regardless of HIV infection, 
and DD, scatter plot showing the distribution of patients and those with ORD as 
classified by biosignature (v). E, ROC curve showing the accuracy of biosignature (v): 
combinations between TB1&TB2 antigen-specific host markers regardless of HIV 
infection, and EE, scatter plot showing the distribution of TB patients and those with 
ORD as classified by biosignature (v). F, ROC curve showing the accuracy of 
biosignature (vi): combinations between TB1&TB2 antigen-specific host markers in 
HIV uninfected individuals, and F, scatter plot showing the distribution of TB patients 
and those with ORD as classified by biosignature (vi).  
 
4.4 Differential expression of host biomarkers detected in QFT Plus 
supernatants in patients with TB disease, individuals with LTBI and those 
without M.tb infection 
 
We evaluated the ability of host markers detected in unstimulated, TB1 and TB2 
antigen-specific QFT Plus supernatants to discriminate LTBI from active TB as well as 
M. tb uninfected individuals. Patients classified as active TB included all the TB 
patients described in previous sections of this thesis whereas those defined as LTBI 




were patients in the ORD group who had positive QFT Plus results, as defined by the 
manufacturer. The patients with ORD, who were QFT Plus negative were classified as 
M. tb uninfected individuals for the purposes of this analysis. 
 
Out of 37 host markers that showed potential in previous studies, 16 markers that were 
detected in the unstimulated supernatants were significantly different between 
individuals with TB and those with LTB1. Among these markers, I-309 (p=0.00006), 
ITAC-1 (p=0.00006), IL-3 (0.00100), IL-33 (p=0.00143), MIG (p=0.003800), and APO-
CIII (p=0.0039) were the top discriminatory between the two groups, with the median 
concentrations of ITAC-1, I-309, IL-3 and IL-33 being higher in TB patients (Table 4.6). 
For the comparison between patients with active TB and the M. tb uninfected 
individuals, eight unstimulated host markers discriminated between the M. tb 
uninfected and TB disease groups including APO-A1 (p=0.0051), MIG (p=0.0061), 
APO-CIII (p=0.0089), ITAC-1 (p=0.0188), and IL-1α. None of the 37 analytes 
unstimulated analytes discriminated between LTBI and M. tb uninfected individuals 
(Table 4.6). 
 
Table 4.6: Differential expression of host biomarkers in unstimulated (nil) 
culture supernatants from patients with TB disease, individuals presenting with 
symptoms suggestive of TB, but who had LTBI and individuals with symptoms 
suggestive of TB, but who were M. tb uninfected. The data shown is for all study 
participants, regardless of HIV infection status. Only markers that showed significant 
differences between any two of the three groups being compared (TB Vs LBI, TB Vs 
Uninfected or LTBI Vs Uninfected) are shown. p-value 1 = active TB Vs, LTBI, p-value 
2 = Active TB Vs M. tb uninfected, p-value 3 = LTBI Vs. M.tb Uninfected 





































0,0071 0,0050 0,9480 














































0,0266 0.0989 0,8296 

































0,0014 0,3298 0,1157 




10 (7-13) 12 (9,0-15) <0,0000 0,0329 0,1423 
GM-
CSF  
46 (24,7-75) 62,2 
(25,5-94) 
35 (22-55) 40 (23,3-
68) 
0,0144 0,1154 0,6294 
IL-1a  47 (26,0-72) 62,5 
(47,2-78) 
43 (21-67) 42 (24,6-
66) 
0,0153 0,0170 0,8926 
IL-10  14 (5,8-33) 16,5 (7,6-
36) 
12 (3-23) 14 (6,2-38) 0,0406 0,4463 0,2876 
IL-22  31 (22,4-42) 36,2 
(30,8-44) 
26 (15-40) 29 (19,0-
43) 
0,0167 0,0859 0,5552 










0,0038 0,0062 0,4384 
IL-3  39 (30,0-45) 44,3 
(38,1-48) 
31 (22-43) 35 (30,9-
43) 
0,0010 0,0250 0,3976 


















0,0279 0,0129 0,2593 
TGF-α 24 (17,8-39) 30,8 
(19,1-51) 
22 (16-32) 25 (17,9-
34) 
0,0227 0,1194 0,4188 
 
 
When the host markers detected in supernatants after stimulation with the TB1 
antigens (TB1-nil) were compared between the three groups, fourteen markers 
discriminated between active TB and LTBI with significant p-values including IL-13 
(p=0.0061), MIP-1α (0.0058), IL-3 (p=0.0216), GM-CSF (p=0.0258), IL-1α (p=0.0333) 
and IL-10 (p=0.0447, with the levels of IL-10 and GM-CSF being higher in patient with 
active TB/LTBI. For the comparison between patients with active TB and M. tb 
uninfected individuals, IP-10 (p=0.0332) and p-selectin (p=0.03665) were surprisingly 
the only two markers which significantly differentiated between the two groups. 
Furthermore, for comparison between individuals with LTBI and the M. tb uninfected 
individuals, IFN-ү (p=0.02734), IL-13 (p=0.02284), IL-22 (p=0.0265), MCP-2 
(p=0.0113), and ITAC-1 (p=0.0114) were markers which showed significant difference 









Table 4.7: Differential expression of TB1 antigen-specific  host biomarkers in 
culture supernatants from patients with TB disease, individuals presenting with 
symptoms suggestive of TB, but who had LTBI and individuals with symptoms 
suggestive of TB, but who were M. tb uninfected. The data shown is for all study 
participants, regardless of HIV infection status. Only markers that showed significant 
differences between any two of the three groups being compared (TB Vs LBI, TB Vs 




Uninfected or LTBI Vs Uninfected) are shown. p-value 1 = active TB Vs, LTBI, p-value 
2 = Active TB Vs. M. tb uninfected, p-value 3 = LTBI Vs. M.tb Uninfected 





























































































































0.0058 0.4944 0.0861 













































































































































0.0638 0.0365 0.0655 





We then evaluated the ability of TB2 antigen-specific host markers (TB2-nil) to 
discriminate TB form LTBI. Nine host markers discriminated TB from LTBI including 
IL-6 (0.0489), IL-13 (0.0041), GM-CSF (0.00300), IL-10 (0.0138), IL-2 (0.0112), and 
MIP-1α (0.0139). For the comparison between patients with active TB and the M. tb 
uninfected individuals, three TB2-stimulated host markers discriminated between the 
M. tb uninfected and TB disease groups including IFN-ү (p=0.0366) and P-selectin 
(p=0.0385) (Table 4.8). Furthermore, for comparison between individuals with LTBI 
and the M. tb uninfected individuals, IFN-ү (p=0.0031), MIP-1α (p=0.0200), IL-22 
(0.0049), IL-13 (p=0.0016), and GM-CSF (p=0.0114) were markers which showed 
most significant between the two groups. The most useful host markers in 
discriminating between groups, regardless of whether they were detected in 
unstimulated, TB1 or TB2 antigen-stimulated samples included IL-10, GM-CSF and 
IL-2. 
 
Table 4.8: Differential expression of TB2 antigen-specific  host biomarkers in 
culture supernatants from patients with TB disease, individuals presenting with 
symptoms suggestive of TB, but who had LTBI and individuals with symptoms 
suggestive of TB, but who were M. tb uninfected. The data shown is for all study 
participants, regardless of HIV infection status. Only markers that showed significant 
differences between any two of the three groups being compared (TB Vs. LBI, TB Vs. 
Uninfected or LTBI Vs Uninfected) are shown. p-value 1 = active TB Vs, LTBI, p-value 









































0.0489 0.3716 0.3251 






























































































































0.0356 0.0385 0.8371 























































Section 4 B 
4.4 Utility of the relatively new host markers evaluated in the current project as 
potential TB diagnostic candidates 
 
We evaluated the concentrations of 20 additional host biomarkers, which have not 
frequently been evaluated in serum, plasma or culture supernatants in the TB field in 
this part of the study. Although some commonly evaluated host markers were part of 
the reagent kit panels, most of these biomarkers were mainly complement proteins 
and other proteins that are produced by various cell types during the immune response 
against infectious conditions. These biomarkers included: complement C2 (CC2), 
CC4b, CC5, CC5a, complement factor D (CFD/adipsin ), mannose binding lectin 
(MBL), complement factor 1 (CF1), soluble intracellular adhesion molecule (sICAM), 
soluble vascular adhesion molecule (sVCAM), D-DIMER, GDF-15, Myeloperoxidase 
(MPO), (Lipocalin2-NGAL), Glial–cell derived neurotropic factor (GDNF), cathepsin, 
platelet derived growth factor (PDGDF-AA), PDGF-AB-BB, plasminogen activator 
inhibitor (PAI1), BDNF (brain derived neurotrophic factor and CCL3. As with section 
4A, we evaluated the utility of individual analytes using the Mann Whitney U test, 
followed by ROC curve analysis. We did not evaluate the usefulness of combinations 
between these biomarkers because of the limited numbers of participants in one of the 
study groups as highlighted below.  
 
4.4.1 Study participants  
 
The individuals in whom the biomarkers evaluated in this section of the study were 
assessed (n= 17) had a mean age of 40.31±11.76. As study participants were selected 
from the biorepository and assessed in a blinded manner, 15 (88.2%) of the 
participants included in this pilot part of the project were finally diagnosed with TB 
disease, with only 3 (17%) being ORD. All the 17 study participants evaluated (Table 
4.9) were a subset of the study participants described in section 4A. 
 
 




Table 4.9 Clinical and demographic characteristics of study participants 
evaluated in section 4B of this dissertation. 
 All TB disease ORD 
No. of patients 18 15 (88.2%) 3 (17.6%) 
Female’s n (%) 7 (41.2%) 4 (57.1%) 2 (28.6%) 
Age mean ± SD 40.31± 11.76 38.95 ±12.26  42.09 ± 13.23 
HIV positive n (%) 1 (5.9%) 0 (0) 0 (0) 
QFT plus Positive n (%) 15 (88.2%) 12 (80%) 3 (17.6) 
QFT plus Negative n 
(%) 
1 (5.9%) 0 (0) 1 (1%) 
Indeterminate n (%) 0 (0) 0 (0) 0 (0) 
 
4.4.2 Utility of individual host markers in the diagnosis of active TB disease 
 
As done for the host markers described in section 4A, we assessed the potential of 
the analytes detected in the nil (unstimulated) culture supernatants and the TB1 and 
TB2 antigen-specific levels separately, using the Mann Whitney U test.  
 
When the concentrations of the 19 host markers were compared between patients 
with TB disease and those with ORD, four markers namely, complement factor D 
(CFD/adipsin), adipsin and sVCAM1 showed significant differences between the two 
groups and their levels were higher in TB patients. None of the other 15 host markers 
showed differences between the two groups (Table 4.10). 
When the TB1 antigen-specific levels of these markers were compared between the 
TB patients and those with ORD using the Mann Whitney test, the levels of sVCAM1 
was significantly elevated in individuals with ORD with none of the other 18 markers 
showing any differences (Table 4.10).  When the TB2-antigen specific levels of the 
markers were assessed, only BDNF concentrations were significantly different 
between the two groups, with the levels of this marker significantly higher in individuals 
with ORD (Table 4.6). Taken together, these results indicate that TB1 and TB2- 
antigen specific levels of most of the 19 relatively new biomarkers evaluated in this 
section of the study may not be useful in the diagnosis of active TB, when evaluated 




in QFT Plus supernatants. However, the limited number of study participants, 
especially the disproportionately lower number of patients in the ORD group does not 
allow for conclusions to be made about the potential usefulness of these host markers. 
It is for this reason that differences between LTBI, active TB and no-M.tb infection 
were not accessed, to avoid over- or under-interpretation of the results. 
 
Table 4.10: Median levels (interquartile ranges in parenthesis) and diagnostic 
accuracies for host biomarkers detected in unstimulated, TB1 and TB2 
stimulated QFT Plus sups from individuals with TB disease or other respiratory 
diseases. Only host markers that showed differences in either the unstimulated, TB1 
























































































Main findings  
The main aim of the current study was to evaluate the usefulness of host biomarkers 
detected in QFT Plus supernatants as diagnostic candidates for active TB disease 
among individuals suspected of having pulmonary TB. Selected host biomarkers that 
showed potential in previous studies including studies done in serum, plasma or 
culture supernatants were evaluated in the QFT Plus supernatants. We furthermore, 
assessed the potential of these biomarkers in discriminating between active TB, LTBI 
and M. tb uninfected individuals as data obtained from such comparison may help in 
enhancing our knowledge of the immune response against TB, especially as relevant 
to the peptide pools used in the recently introduced QFT Plus test.  
The main findings of the work presented in this chapter, included the identification of 
multiple host biomarkers that are detectable in QFT Plus supernatants including 
markers detected in the nil, TB1 and TB2 stimulated tubes, which showed potential 
individually in the diagnosis of TB disease, as well as combinations between different 
biomarkers which showed strong potential as presented in table 4.5. The potentially 
most useful individual host biomarkers detected in either unstimulated, TB1 or TB2 
antigen-stimulated supernatants for the diagnosis of active TB as determined by AUC 
included ITAC-1, IL-3, I-309, MIG, Apo-A1, P-selectin, MIP-1α, EGF, GM-CSF, IL-2  
and IL-10. Biomarkers that might not necessarily have shown potential individually, 
but that formed parts of various combinations of analytes, representing the 
biosignatures from nil, TB1 and TB2 antigen-specific, or TB1+TB2 antigen-specific 
biosignature as shown in table 4.5 included NCAM-1, MCP-2, CFH, TGF-α LIGHT, 
Apo-CIII and ITAC-1. Furthermore, host markers which discriminated active TB from 
LTBI and M. tb uninfected included MIP-1 α, IL-3, CD40L, IP-10, MCP-2, IL-1 α, IFN-
γ and ITAC-1. These host markers may therefore represent the most important 
candidate biomarkers which may be taken forward for further investigations in future 
larger studies. However, as the main purposes of the present study was to evaluate 
the usefulness of biomarkers detectable in QFT Plus supernatants in the diagnosis of 
active TB amongst individuals with suspected TB, the most accurate biosignature for 
the diagnosis of TB disease in all study participants, regardless of HIV infection or 
QFT Plus results was a combination between APO-CIII, ITAC-1, MIG, MCP-2, I-309, 




and NCAM-1.  This biosignature diagnosed TB disease in all study participants with a 
sensitivity of 73.9% and specificity of 83.7%. 
Study strength and weaknesses of the present study 
Several studies have demonstrated the potential of host markers detected in 
supernatants obtained after stimulation of whole blood cells in previous generations of 
QuantiFERON in the diagnosis of TB disease. The current study was about host 
markers detected in QFT Plus supernatants, a new generation of QuantiFERON test 
which consist of an additional antigen stimulation tube (TB2). Based on literature 
searches, there are as yet no studies that reported on the potential utility of host 
markers detected in especially QFT Plus supernatants in the diagnosis of TB disease 
in individuals in whom TB is suspected (phase III diagnostic studies as done in the 
present study. We have shown in the current study that some of the host markers that 
were described in previous studies (125) may also be useful, when measured in QFT 
Plus supernatants in the diagnosis of TB disease. 
The study participants included in the current study were the same participants 
included in the study reported in chapter 3. As already discussed in that chapter, a 
phase III study, such as described in the present study is the best study design for 
evaluating the accuracy of diagnostic biomarkers or tests, especially when done 
blindly as was the case in the current project. The fact that this study was conducted 
in an area with one of the highest burdens of TB disease in the world, with a high 
prevalence of LTBI (6), strengthens the findings, especially regarding possible use of 
any biomarkers identified in the project in the diagnosis of active TB. However, the use 
of only a single study site in the project may be seen as a limitation. That 
notwithstanding, the findings from a phase III study such as this will be very relevant 
and will be informative in the design of future studies, including studies done at multiple 
sites, e.g. in other African countries or other continents.  Although, this study had 
reasonable sample size, the small number of HIV infected individuals led to the 
inability of this study to assess the effect of HIV infection on the performance of the 
current individual host markers which showed potential in diagnosing and 
differentiating TB between active TB and other respiratory diseases as well as M tb 
uninfected individuals. Although the current study discovered new host markers which 
showed potential in diagnosing TB disease, the disproportionately lower number of 




ORD group did not allow us to make any conclusions about the usefulness of these 
new markers. Furthermore, we were unable to evaluate all markers from previous 
studies which showed potential in diagnosing TB disease due to the fact that the 
luminex kits used in this study had already been purchased before the beginning of 
this study. Although most of the markers in unstimulated supernatants seemed to not 
be affected by HIV infection, small number of active TB individuals with HIV infection 
made it impossible for us to compare the effect of HIV infection in the performance of 
individual host markers between the two groups. 
Relation of the current study with other studies 
In previous work done at the Stellenbosch University Immunology Research Group 
laboratory (SU-IRG), host biomarkers other than IFN-γ which were detected in culture 
supernatants left over after the QuantiFERON TB Gold In Tube test showed potential 
as diagnostic biomarkers for active TB disease and for discriminating between active 
and latent M. tb infection in both adults and children (100, 102, 118, 134, 135). The 
biomarkers identified in these studies were put together and evaluated in a larger 
Africa wide project that included seven institutions situated in six different countries, 
with this larger study validating some of the analytes described in the single site study 
(100). Other recent studies from the group indicated that biomarkers detected in 
unstimulated samples including serum, plasma and saliva showed potential in the 
diagnosis of TB disease (112, 113). As no previous studies have evaluated the 
usefulness of these biomarkers in the supernatants obtained after stimulation of blood 
cells with the antigens used in the recently introduced QFT Plus test, it was imperative 
that the potential value of these biomarkers in this test system be established. Out of 
the 15 host markers that showed potential in diagnosing TB disease in unstimulated 
QFT Plus supernatants in this study, four individual host makers (ITAC-1, IL-3, I-309 
and MIG) which were amongst the best of these analytes were described as showing 
potential in a previous study by Jacobs et al (112). Furthermore, other host biomarkers 
which showed potential including EGF, TGF-α, IL-2, IL-33, APO-A1, ADAMTS13, GM-
CSF and IP-10 also showed potential in previous studies (100, 101, 118, 120).  The 
findings from the present study are therefore in agreement with these published 
studies which were based on QFT In Tube supernatants.  




One of the markers that showed potential in the present study (IL-3) is a cytokine that 
is secreted by basophils and activated T cells and helps in improving natural host 
immune response against diseases (137). It was the second best individual host 
marker which diagnosed TB disease with promising sensitivity and specificity. IL-3 
concentrations were significantly higher in TB patients in comparison to patients with 
ORD and this was only observed in the unstimulated and not the TB1 or TB2 
stimulated samples. This may suggest that IL-3 may be a useful baseline biomarker, 
which may be detectable in simple serum, plasma or finger-prick based tests for 
differentiating TB from Non TB patients. ITAC-1 is a chemokine which is known to 
attract activated T cells to the site of infection. This chemokine showed promise in 
diagnosing TB disease either as a single marker or in combination with other 
cytokines. A previous study by Jacobs et al (112) showed that ITAC-1 has potential in 
diagnosing TB disease in plasma which is consistent with findings from our current 
study. Other chemokines such as I-309, MCP-1, MIP-1α showed promise in 
diagnosing TB disease. The most promising TB1 and TB2 antigen-specific host 
markers identified in this study including P-selectin, MIP-1, GM-CSF, IL-10, IL-2 and 
LIGHT are amongst the mostly investigated biomarkers for diagnosis of TB disease.  
It is widely known that CD4 T cells play an important role in the immune response 
against M. tb infection through production of IFN-ү and other host markers. However, 
in addition to CD4 T-cells, evidence from previous studies have shown that CD8 T 
cells also play an important role during M.tb infection through production of cytokines 
(138). Cytokines produced by CD8 T cells either activate macrophages which 
suppressed the growth of M. tb or directly lyse M. tb intracellularly (138). The addition 
of CD8+ peptides (TB2) in the QFT Plus test is hypothesised to have increased 
sensitivity for diagnosing M. tb infection as well as active TB (139, 140, 73). In this 
study, the most promising antigen-specific host markers for the diagnosis of active TB 
were mostly anti-inflammatory cytokines and growth factors which have previously 
been associated with the disease. Two growth factors (EGF and TGF- α) showed 
significant differences between TB patients and ORD groups and were detectable in 
the TB2 antigen stimulated and not the TB1 culture supernatants. EGF stimulates cell 
growth and differentiation amongst other functions, a study by Bermudez and 
colleagues demonstrated that EGF enhances the growth rate of extracellular and 
intracellular M. tb in the site of infection (141). Another study by Chegou et al also 




reported the upregulation of these growths in factor of active TB individuals (100). 
Transforming growth factor (TGF- α) plays an important role as an EGF receptor 
ligand, which activates the signalling pathway for proliferation, activation and 
development of the cell. Since TB2 antigen tube contains peptides which stimulates 
both CD4 and CD8 T cell immune response, the presence of these growth factors only 
in TB2 antigen tube may indicate that CD8 T cells were the main cells which stimulated 
EGF and TGF-α not CD4 T cells as these responses were not observed in TB1 culture 
supernatants. Although EGF levels were not significantly different between ORD and 
TB groups, the presence of these markers only in TB2 confirms the role for CD8 T cell 
immune function during TB disease as CD8+ T cells have been reported to be 
associated with active TB or M. tb bacterial loads (73). However, this does not fully 
explain previous observations about EGF in previous studies. Therefore this finding 
requires further investigation. 
Although there are no biomarkers approved for differentiating LTBI from active TB yet, 
hence there is no gold standard for LTBI, many studies have shown various markers 
which are differentially expressed between people with TB, without TB and with other 
respiratory diseases (101,114,) and also markers discriminating between LTBI, 
healthy controls and active TB (101). Host markers which showed great potential in 
discriminating active TB from LTBI either in stimulated or unstimulated supernatants 
were mostly pro/anti-inflammatory cytokines/chemokines, growth factors and few 
other proteins. During adaptive immune response to M. tb infections, it is known that 
CD4+ and CD8+ T cells are the main cells involved during host immune defence 
against  M. tb. During these response, cytokines such as IL-2 and IFN-ү plays different 
roles including signalling, activation, development, proliferation and control of the 
infection. This may explain the why different host markers were found in unstimulated 
supernatants.  A study by Nonghanphithak et al (142), showed that IL-2 and MCP-1 
may have potential in discriminating between active TB and LTBI. In our study IL-2 
and ITAC-1 were the most informative host markers for discrimination between active 
TB, LTBI and M. tb uninfected , and they were also common markers between antigen 
stimulated and unstimulated QFT Plus supernatants.  In a meta-analysis study for host 
markers in discrimination of LTBI from TB, IL-2 was found to be a valid marker to 
discriminate TB from LTBI with a high pooled sensitivity and specificity (143). Worth 
noting, IP-10 and P-selectin were the only antigen stimulated host markers which 




significantly discriminated TB from M. tb uninfected individuals. This was surprising as 
it was expected that biomarkers differentiating between LTBI and active TB would also 
differentiate between active TB and uninfected controls if these are the groups and 
after re-analysis of the data. In the previous study by Chegou et al (102), the same 
phenomenon was observed, but not for all biomarkers. Therefore, the reason for this 
is unknown but requires further evaluation in other studies. Since QFT Plus relies on 
T cell mediated immune response. The difference and changes of the discriminative 
host markers could be due to the M. tb burden or antigen load. The ability of IP-10 to 
discriminate these two groups in the present study is in agreement with previous 
studies which have shown its importance during active TB (99,144-146).  
Although individual host biomarkers showed potential, combinations between host 
markers were more promising as diagnostic signatures as has been observed in other 
studies. In a study by Eun-Jung Won et al (147), a combination of stimulated and 
unstimulated levels of GM-CSF, IL-2, and IL-3 in QFT-GIT supernatants correctly 
discriminated between 100% of M. tb uninfected and 92.06% M. tb infected groups. In 
a more recent study by Chegou et al, combinations of various host markers including 
TGF-α and MIP-1β diagnosed TB disease regardless of HIV infection with sensitivities 
above 80 % (100). In the current study, the most accurate combination of host markers 
was a combination of six markers in unstimulated QFT Plus supernatants (Apo-ACIII, 
MIG, ITAC-1, MCP-2, I-309 and NCAM-1) which diagnosed TB disease regardless of 
HIV status with sensitivity and specificity >70%. However, when only HIV uninfected 
individuals were considered, another combination of markers MIG, I-309, MCP-2 and 
NCAM-1 diagnosed TB disease with an increased sensitivity and specificity >80%. 
The increased sensitivity and specificity after excluding HIV infected individuals 
therefore indicated that HIV has an influence in performance of host biosignatures in 
unstimulated QFT Plus supernatants. Furthermore, combinations between host 
markers detected in both TB1 and TB2 antigen stimulated tubes resulted in two 
biosignatures which diagnosed TB disease with accuracies >70%. When both antigen 
tubes were combined, the combination of host markers resulted in an increased 
accuracy for diagnosis of TB disease. These data indicate M. tb antigen-specific and 
also unspecific responses detectable in QFT Plus supernatants may contribute to 
adjunctive diagnosis of TB disease. However, given recent showing that biomarkers 
detectable in serum, plasma, urine and saliva samples may be useful and even 




performed better than the accuracy obtained for QFT Plus supernatants in the current 
study as per literature reports (103,104,106,107, 112), the place of QFT Plus based 
host biomarkers might be limited and such biomarkers may be relevant to specific 
niche groups, but more research is needed to ascertain the place of such biomarkers 
in the TB diagnostic landscape. 
Implications of the study  
Although tests based on ex vivo samples may be more rapid and so be more useful in 
the diagnosis of TB disease as discussed in the previous paragraph, there are no 
diagnostic tests based on these samples currently in the market. Potential tools based 
on these sample types are still under development. During the evaluation of the 
performance of such tools in routine clinical settings in the TB programs, it may be 
realised that antigen-specific biomarkers might still play a role, in terms of specificity 
of the tests for TB disease, since biomarkers from ex vivo samples will be unspecific 
to TB. Given the roles of cytokines/chemokines/growth factors in immune response 
against M. tb antigen stimulated markers can be used in diagnosing TB disease in low 
TB endemic settings or in people with difficult to diagnose TB such as extrapulmonary 
TB (150). Furthermore, elevation of unstimulated host markers provides a good basics 
for the development of a more rapid test to detect M. tb or active TB (149). 
Furthermore, a blood-based point-of-care screening test for active TB which is based 
on the detection of host biomarkers in blood samples is currently under development 
and clinical evaluation in our research group (www.screen-tb.eu). Therefore, host 
markers detected in the current study especially, markers that were detected in 
unstimulated culture supernatants are amongst the biomarkers that are on the 
ScreenTB test that is currently under development. These host markers can be used 
for optimisation of point-of-care diagnostic tests for TB disease in resource-
constrained settings. More diagnostic tools at a point of care will be easily accessible 
to anyone for early diagnosis and then treatment will be initiated early. This prevents 
transmission and risk of drug resistance. 
Unanswered questions and future suggestions 
In the current study, we identified multiple candidate biomarkers and biosignatures 
which showed potential in the diagnosis of TB disease amongst people who were 
suspected of having TB disease. The biosignatures shown in table 4.5 represent the 




best signatures from unstimulated, TB1 antigen-stimulated, TB2 antigen stimulated 
and TB1& TB2 antigen stimulated tubes, with performances in only HIV uninfected 
individuals shown for some of the biosignatures. Due to the design of the project, 
analysis of study participant samples blindly and assaying on plates in the order in 
which they were recruited, there was a disproportionately low number of people with 
ORD in the samples on which panels containing the relatively new biomarkers (same 
panels contained some well-known markers) were investigated. Results from that 
specific analysis (Section 4B) are therefore not conclusive. Therefore the true potential 
of these biomarkers as possible diagnostic biomarkers in unstimulated or QFT Plus 
antigen-stimulated samples remains unknown, even though significant differences 
and promising AUCs were obtained for some. Taking the findings as shown in the 
applicable tables in section 4B may be considered as over- or under-statement of the 
study’s findings. Future studies should evaluate all the promising analytes identified in 
the present study with more study participants. Participants included in such studies 
should include children and adults, both with suspected pulmonary and 
extrapulmonary TB. HIV infected individuals included in such studies should be 
properly staged e.g. with viral loads or CD4 counts so that the influence of severe HIV 
infection on the host makers may be determined. Data obtained from the current study 
may be used in power calculations to ensure that these future studies are well-
powered. These future studies will need to be done in other African countries and other 
continents to determine the global relevance of the findings. 
Conclusion 
In conclusion, this was the first study to demonstrate that host biomarkers detected in 
QFT Plus supernatants may be useful as diagnostic candidates for TB disease, in high 
burden settings. Although findings from this study hold promise in improving TB 
diagnosis, more studies are needed to confirm the findings from the study. In light of 
the recent finding showing that ex vivo host biomarkers obtained in serum, plasma, 
saliva and urine samples may be useful in the diagnosis of TB, it will be necessary 
that future studies determine the best scenarios where biomarkers detected in M .tb 
stimulated samples may be useful. Such information may then be useful in the 
development of novel diagnostic tools that may be useful in the diagnosis of TB 
disease in specific clinical circumstances where the tools currently being developed 
may have limitations. 





Summary and conclusion 
5.1 Thesis overview  
 
As discussed in previous chapters within this thesis, proper control of TB is dependent 
on early diagnosis of the disease and early initiation of treatment. Several highly 
publicised limitations of the currently existing diagnostic tests include poor sensitivity, 
long turn-around times and, high costs amongst others. TB therefore remains a global 
problem because of these reasons. However, recent studies have shown that 
measurement of the concentrations of host biomarkers which are detectable in 
plasma, serum, M. tb antigen-stimulated supernatants and other sample types may be 
useful in diagnosing TB disease. The importance of especially diagnostic approaches 
based on host immunological biomarkers is that they can be easily incorporated into 
simple point-of-care tests. Therefore, the main aim of this thesis was to evaluate the 
potential of host biomarkers detected in culture supernatants obtained from stimulation 
of whole blood samples in the recently developed QuantiFERON® TB GOLD Plus 
(QFT Plus) supernatants as biomarkers for the diagnosis of TB disease. This was 
done in study participants who presented with symptoms requiring investigation for TB 
disease at a primary health care centre in Cape Town, an area with a high burden of 
TB. As the QFT Plus is a relatively new test, we also evaluated the usefulness of the 
test in this study population, especially as the manufacture claims a sensitivity >95% 
and also whether when used in combination with symptoms the test had potential in 
the diagnosis of TB disease in people suspected of having active TB. 
 
 5.2 Summary of findings 
 
In chapter 3 we evaluated the usefulness of QFT Plus in the diagnosis of TB disease 
in people suspected of having active TB in a high burden setting. The sensitivity and 
specificity of the QFT Plus test in our setting was 77% and 71% respectively. When 
QFT Plus was used in combination with TB symptoms (8 symptoms including 
coughing, night sweats, feverish, weight loss, chest pains, weak and tiredness as well 
as not feel like eating), three symptoms including coughing, weight loss and feverish 




diagnosed TB disease with the same accuracy as the QFT Plus test (sensitivity of 77% 
and specificity of 70%) and when the QFT Plus positive results were used in 
combination with symptoms, the addition of QFT Plus did not have any additional value 
over the symptoms alone. On the contrary, QFT Plus positive results + symptoms 
resulted in inferior accuracy to the QFT Plus alone or combination of symptoms alone. 
In chapter 4, we evaluated the potential of 37 biomarkers in unstimulated and TB 
antigen-stimulated QFT Plus supernatants as candidates for diagnosis of TB disease. 
In unstimulated supernatants, 14 host markers showed potential for diagnosing TB 
disease as determined by the area under the ROC curves (AUC). From these host 
markers, ITAC-1, IL-3, I-309, MIG, and APO-CIII were the top individual markers. In 
TB1 antigen stimulated supernatants, seven host markers including p-selectin, MIP-
1α, and TGF-α, IL-13, GM-CSF and IL-10 showed potential. In TB2 antigen stimulated 
supernatants, six host markers including p-selectin, MIP-1α, GM-CSF, LIGHT, IL-13, 
GM-CSF and IL-10 showed potential as individual host markers.  
 
Despite the potential shown by individual host markers in diagnosing TB disease, 
combinations between different host markers were more promising in all antigen 
stimulation conditions.  In unstimulated culture supernatants, the most promising 
biosignature that diagnosed TB disease regardless of HIV status or QFT Plus results 
included a six-maker biosignature comprising of Apo-A1, ITAC-1, I-309, MIG, MCP-2 
and NCAM; diagnosing TB with an AUC >0.91, sensitivity of 73.91% (95% CI, 51.6-
89.8%) and specificity of 86.2% (95% CI, 75.3-93.5%) after leave-one-out cross 
validation. However, it was shown that unstimulated host markers were affected by 
HIV infection, given that in only HIV uninfected individuals, a four-marker biosignature 
comprising of Apo-CIII, I-309, MIG and NCAM diagnosed TB disease with better 
accuracy (an AUC >0.91 (0.85-0.98), with sensitivity and specificity of 76.5% (95% CI, 
50.1-93.2%) and 85.7% (95% CI, 74.6-93.3% respectively after leave-one-out cross 
validation). In TB1 antigen stimulated supernatants, the most useful biosignature in all 
study participants was a four marker combination between I-309, TNF-α, MIP-1α and 
CFH , which diagnosed TB disease with an AUC of 0.72, sensitivity of 60.0% and 
specificity of 78.8% after leave-one-out cross validation. In TB2 antigen stimulated 
supernatants, the most useful biosignature in all study participants was a four marker 
combination between IL-6, MIP-1α, GM-CSF and TGF-α, which diagnosed TB disease 
with an AUC of 0.72, sensitivity of 60.0% and specificity of 78.7% after leave-one-out 




cross validation,. When TB1 and TB2 antigen-specific host biomarkers were 
combined, the most useful biosignature was a four combination of TNF-α. LIGHT, MIP 
and P-Selectin which diagnosed TB disease with an AUC of 0.84 corresponding to 
sensitivity of 48.6% specificity of 87.3% after leave-one-out cross validation. A second 
biosignature showed promised in diagnosing TB disease was when TB1 was 
combined with TB2. The biosignature comprised of TNF-α, LIGHT, MIG, and p-selectin 
which diagnose TB disease with sensitivity and specificity of 77.3% (95% CI, 54.6-
92.2%) and 72.3% (95% CI, 59.8-82.7%) respectively. After leave-one-out cross 
validation, the sensitivity and specificity of the biosignature were 77.3% (95% CI, 54.5-
92.2%) and 69.2% (95% CI, 56.6-80.1%) respectively.  
 
Given that 71.1% of the patients with ORD were infected with M. tb according to the 
QFT Plus test, we evaluated whether these host protein biomarkers were differentially 
expressed between patients with active TB, individuals with LTBI and M. tb uninfected 
individuals. As shown in table 4.6 of chapter 4, the most important unstimulated host 
biomarkers that discriminated between LTBI and active TB included I-309, ITAC-1, IL-
3, those that discriminated between TB and M. tb uninfected individuals included APO-
A1, MIG and APO-CIII, and surprisingly, there were no significant differences between 
LTBI and M. tb uninfected individuals for any of the 37 biomarkers evaluated in all 
study participants. The most important TB1-stimulated host biomarkers that 
discriminated between LTBI and active TB included MIL-1α, GM-CSF, IL-3, 
surprisingly those that discriminated between TB and M. tb uninfected individuals only 
included IP-10 and P-Selectin and , for comparison between individuals with LTBI and 
the M. tb uninfected individuals, IFN-ү, IL-13 , IL-22 , MCP-2 , and ITAC-1. 
Furthermore, the most important TB2-stimulated host biomarkers that discriminated 
between LTBI and active TB included IL-6, GM-CSF, IL-2 and IL-10,  those that 
discriminated between LTBI and M. tb uninfected individuals included IFN-γ,MIP-1α, 
IL-3, IL-22  and GM-CSF, for comparison between individuals with LTBI and the M. tb 
uninfected individuals, IFN-ү, IL-13 , IL-22 , MCP-2 , and ITAC-1. Surprisingly those 
that discriminated between TB and M. tb uninfected individuals only included IFN-ү 
and P-selectin. The most useful host markers in discriminating between groups, 
regardless of whether they were detected in unstimulated, TB1 or TB2 antigen-
stimulated samples included IL-10, GM-CSF and IL-2. 
  





5.3 Significance of the finding from this thesis 
 
This was the first study to evaluate the performance of host markers in QFT Plus 
supernatants, at least in a setting with one of the highest burdens of TB in the world. 
Findings from this work are being written up for submission for peer review and 
publication and will contribute to knowledge about the potential utility of these host 
markers especially in high burden settings. The findings on the accuracy of the QFT 
Plus test in patients presenting with symptoms in this study are also very relevant, 
given the high sensitivity and specificity promised by the test manufacturer in the 
package insert. The strong study design (phase III) of the parent study adds to the 
high relevance of findings from the project, opposed to several QFT In tube-based 
previous studies which were based on a case-control design. It is known that case-
control studies tend to over-estimate the accuracy of diagnostic studies (132). It is now 
known whether the high accuracy values reported by the manufacturer in the package 
insert were based on such studies or in studies conducted in extreme groups. Our 
study’s findings are therefore highly relevant regarding the performance of the QFT 
Plus test and also host biomarkers detected in QFT Plus culture supernatants in the 
real-world setting, in high burden countries. In light of the recent finding showing that 
ex vivo host biomarkers obtained in serum, plasma, saliva and urine samples may be 
useful in the diagnosis of TB, it will be necessary that future studies determine the best 
scenarios where biomarkers detected in M .tb stimulated samples may be useful. 
Furthermore, a blood-based point-of-care screening test for active TB which is based 
on the detection of host biomarkers in blood samples is currently under development 
and clinical evaluation in our research group (www.screen-tb.eu). Although the main 
aim of this chapter was to evaluate antigen specific host markers, unstimulated host 
markers performed better when compared to the stimulated host markers and are 
amongst the biomarkers that are on the ScreenTB test that is currently under 
development. These host markers can be used for optimisation of point-of-care 
diagnostic tests for TB disease in resource-constrained settings. Furthermore, tests 
based on ex vivo samples may be more rapid and useful in the diagnosis of TB 
disease, however, there are no diagnostic tests based on these samples currently in 
the market. During the evaluation of the performance of such tools in routine clinical 




settings in the TB programs, antigen-specific biomarkers might still play a role, in terms 
of specificity of the tests for TB disease, since biomarkers from ex vivo samples will 
be unspecific to TB. Given the roles of cytokines/chemokines/growth factors in 
immune response against M. tb antigens, stimulated markers can be used in 
diagnosing TB disease in low TB endemic settings or in people with difficult to 
diagnose TB such as extrapulmonary TB.  
 
5.4 Direction for future studies 
 
Although the main aim of this study was to evaluate the antigen stimulated host 
biomarkers/biosignature, host biosignature in the unstimulated QFT Plus supernatants 
showed better accuracy for diagnosing TB disease and the combination of these 
markers has never been shown in any study. Future studies should therefore evaluate 
this biosignature in ex vivo samples as elevation of unstimulated host markers found 
in this study may provide a good basis for the development of more rapid tests to 
detect M. tb or active TB. As HIV co-infection may have influence on the performance 
of individual host markers as indicated by findings from the current study, it may be 
important to include more properly staged HIV co-infected (low/high CD4 count, viral 
loads) individuals in future studies as discussed in chapter 4. Cytokine profiles of M. 
tb-specific T cells have been studied with the aim of finding a correlation with M. tb 
infection. However, existing data are currently inconclusive due to contrasting findings 
on the distribution of the various cytokine-producing CD4+ and CD8+ T cell subsets. 
Furthermore, few studies have been conducted on cell types producing the biomarkers 
that are detectable in serum and plasma samples during M. tb infection. Human 
immune responses to M. tb may also lead to transcriptional patterns in blood that are 
not present in other conditions. RNA transcripts have shown ability to distinguish 
tuberculosis from other diseases, but most of the studies to date were conducted in 
unstimulated blood samples as obtained with RNA obtained from Paxgene tubes and 
not RNA obtained from M. tb specific antigen stimulated blood cells.  In the course of 
my MSc studies, I collected sediments that were left over after performance of the QFT 
test. These sediments were either cryopreserved for flow cytometry or stored in RNA 
later. Therefore future studies may use these sediments for the investigation of novel, 
M. tb specific transcriptomic biosignatures for active TB disease. As flow Cytometry, 




is a potential tool to improve TB diagnosis by phenotypical and functional 
characterization of antigen-specific T cells, information obtained about the expression 
of biomarkers intracellularly or at the surface of cells may help improve our 
understanding of T cell immunology- especially as related to M. tb antigen-specific 
stimulation of blood cells as obtained with the sediments stored after stimulation with 
the antigens employed in QFT Plus supernatants in my MSc project. Therefore there 
are many opportunities for future follow-on studies from this project, given that little is 
known about the immunology of M. tb infection especially regarding what constitutes 
protective immunity, correlates or protection, correlates of risk or biomarkers for TB 
treatment monitoring. The findings from the work conducted in the course of my project 
including findings from the stored, unused samples mentioned above may help shed 
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